var title_f40_40_41600="Mammogram of nipple inversion associated with malignancy";
var content_f40_40_41600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram of nipple inversion associated with malignancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroareolar breast cancers, within 2 cm of the nipple areolar complex, are likely to be associated with nipple inversion as shown here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41600=[""].join("\n");
var outline_f40_40_41600=null;
var title_f40_40_41601="Patient information: Pterygium (The Basics)";
var content_f40_40_41601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86732\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/19/33087\">",
"         Pterygium",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/29/31185\">",
"         Patient information: Blepharitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/61/29649\">",
"         Patient information: Photokeratitis (Arc eye) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pterygium (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H80269114\">",
"      <span class=\"h1\">",
"       What is a pterygium?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pterygium is an abnormal growth on the eye (",
"      <a class=\"graphic graphic_picture graphicRef86731 \" href=\"mobipreview.htm?32/19/33087\">",
"       picture 1",
"      </a>",
"      ). It is a triangle-shaped area of tissue that grows from the corner of the eye towards the center. The tissue can be thin and white or thicker and pink or red. Some people get a pterygium in both eyes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269129\">",
"      <span class=\"h1\">",
"       What are the symptoms of a pterygium?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A white or pink growth that partly covers the eye",
"       </li>",
"       <li>",
"        Eye redness",
"       </li>",
"       <li>",
"        Eye discomfort",
"       </li>",
"       <li>",
"        Blurry vision",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A few people only notice a pterygium when it starts to cover the iris. The iris is the colored part of the eye.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269144\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have blurry vision or other vision problems, or if you notice a growth on your eye.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269159\">",
"      <span class=\"h1\">",
"       Is there a test for a pterygium?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your doctor or nurse should be able to tell if you have a pterygium by doing an exam and talking with you. The doctor will also check that the growth is a pterygium and not a different eye condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269174\">",
"      <span class=\"h1\">",
"       How is a pterygium treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/31/3572?source=see_link\">",
"         Artificial tears",
"        </a>",
"        &rdquo; &ndash; These can help with redness and irritation. You can buy artificial tears at the drug store or grocery store without a prescription. They come in liquid eye drops, gels, or ointments. Your doctor or nurse can help you decide which form is best for you.",
"       </li>",
"       <li>",
"        Prescription eye drops, gels, or ointments &ndash; If over-the-counter",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/31/3572?source=see_link\">",
"         artificial tears",
"        </a>",
"        do not help.",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors might remove the pterygium if:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        It causes serious vision problems, or will soon.",
"       </li>",
"       <li>",
"        It keeps the eye from moving normally.",
"       </li>",
"       <li>",
"        It causes serious irritation that does not go away with other treatments.",
"       </li>",
"       <li>",
"        It makes the eye look very strange and this affects your life a lot.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is common for a pterygium to come back after surgery. If it does, it can be harder to get rid of the next time. So doctors usually do surgery only if a pterygium causes serious problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269189\">",
"      <span class=\"h1\">",
"       Can a pterygium be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Protecting your eyes from the sun could help, especially if you spend a lot of time outdoors. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear a hat when you are outdoors.",
"       </li>",
"       <li>",
"        Wear sunglasses that fit well and block UVA and UVB rays. The label on the sunglasses will say what type of rays they block. If you wear prescription sunglasses, make sure they block both types of UV rays.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H80269204\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/29/31185?source=see_link\">",
"       Patient information: Blepharitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/61/29649?source=see_link\">",
"       Patient information: Photokeratitis (Arc eye) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/40/41601?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86732 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41601=[""].join("\n");
var outline_f40_40_41601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269114\">",
"      What is a pterygium?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269129\">",
"      What are the symptoms of a pterygium?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269144\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269159\">",
"      Is there a test for a pterygium?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269174\">",
"      How is a pterygium treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269189\">",
"      Can a pterygium be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80269204\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/19/33087\">",
"      Pterygium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/29/31185?source=related_link\">",
"      Patient information: Blepharitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/61/29649?source=related_link\">",
"      Patient information: Photokeratitis (Arc eye) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41602="Shoulder extension exercise for scapular stabilizers";
var content_f40_40_41602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86028/Sh_exten_scap_stabil_video.mp4?title=Shoulder+extension+exercise+for+scapular+stabilizers\" style=\"width:496px;height:304px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder extension exercise for scapular stabilizers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shoulder extension exercises performed against resistance are among the exercises used to strengthen the muscles that stabilize the scapula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41602=[""].join("\n");
var outline_f40_40_41602=null;
var title_f40_40_41603="Myeloma cast I-light microscopy";
var content_f40_40_41603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myeloma cast : Light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power light micrograph shows PAS stain of tubular casts in myeloma kidney. The bottom two tubules contain casts composed of PAS-negative immunoglobulin light chains (small arrows). In comparison, the cast in the middle tubule (probably hyaline) is primarily composed of PAS-positive Tamm-Horsfall mucoprotein, the matrix of all casts (large arrow). Myeloma proteins are PAS-negative because they contain few of the neutral sugars that are detected by this stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41603=[""].join("\n");
var outline_f40_40_41603=null;
var title_f40_40_41604="Amoxapine: Patient drug information";
var content_f40_40_41604=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amoxapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/52/13127?source=see_link\">",
"     see \"Amoxapine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701510",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amoxapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10871 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41604=[""].join("\n");
var outline_f40_40_41604=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018411\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018413\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018412\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018417\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018418\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018420\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018415\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018416\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018421\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018422\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/52/13127?source=related_link\">",
"      Amoxapine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41605="Lamotrigine: Patient drug information";
var content_f40_40_41605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lamotrigine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     see \"Lamotrigine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     see \"Lamotrigine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LaMICtal&reg;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; ODT&trade;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; XR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lamotrigine&reg;;",
"     </li>",
"     <li>",
"      Auro-Lamotrigine;",
"     </li>",
"     <li>",
"      Lamictal&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lamotrigine;",
"     </li>",
"     <li>",
"      PMS-Lamotrigine;",
"     </li>",
"     <li>",
"      ratio-Lamotrigine;",
"     </li>",
"     <li>",
"      Teva-Lamotrigine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. Children may be most likely to get these. Most happen within a few weeks of starting this drug but some show up after months of use. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lamotrigine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Chewable dispersible tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be swallowed whole, chewed, or mixed in water or fruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If chewed, drink a little water or fruit juice to help swallow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may break up tablet by adding liquid to cover tablet in a glass or spoon. Wait at least 1 minute until fully broken up, then mix and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10788 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-97C5FA2E12-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41605=[""].join("\n");
var outline_f40_40_41605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030581\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030583\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030582\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030587\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030588\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030590\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030585\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030586\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030591\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030592\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=related_link\">",
"      Lamotrigine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=related_link\">",
"      Lamotrigine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41606="TB chest radiograph 2";
var content_f40_40_41606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Chest radiographs of different presentations of tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Primary tuberculosis in a child (note the right-sided hilar adenopathy, right-sided lower lobe infiltrates, and volume loss).",
"    <br>",
"     (B) Lower lung field tuberculosis infiltration and cavity with air-fluid level in lingula.",
"     <br>",
"      (C) Reactivated tuberculosis, far-advanced disease with bronchogenic spread.",
"      <br>",
"       (D) Miliary tuberculosis.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41606=[""].join("\n");
var outline_f40_40_41606=null;
var title_f40_40_41607="Clinical presentation and diagnosis of obstructive sleep apnea in adults";
var content_f40_40_41607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     Lewis R Kline, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41607/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/40/41607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas and hypopneas caused by repetitive collapse of the upper airway during sleep. The diagnosis should be considered whenever a patient presents with risk factors or clinical manifestations that are compatible with OSA. The challenge is to select the patients who are most likely to have OSA for further diagnostic evaluation, since expensive and time consuming testing has traditionally been required to identify OSA.",
"   </p>",
"   <p>",
"    The clinical presentation, clinical features, diagnostic approach, and differential diagnosis of OSA are reviewed here. The epidemiology, risk factors, pathogenesis, natural history, and management of OSA are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with OSA first come to the attention of a clinician because the patient complains of daytime sleepiness, or the bed partner reports loud snoring, gasping, snorting, or interruptions in breathing while sleeping. These symptoms may be presenting complaints, reported during the evaluation of another complaint, detected during health maintenance screening, or reported during preoperative screening. Regardless of how the complaints are identified, all patients who report daytime sleepiness or snoring, gasping, snorting, or interruptions in breathing while sleeping, should be asked about and examined for other features of OSA. This information is important for determining which patients require diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13336404\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of OSA may be identified by medical history, physical examination, or evaluation of laboratory test results (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"mobipreview.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daytime sleepiness is a common feature of OSA. However, it may go unnoticed or its significance may be underestimated because of its insidious onset and chronicity. The patient may not describe the symptom as sleepiness, but may use other terms, such as fatigue, tiredness, and low energy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/1\">",
"     1",
"    </a>",
"    ]. Careful questioning of the patient typically reveals a pattern of feeling sleepy or falling asleep in boring, passive, or monotonous situations. As an example, the patient may admit to consistently falling asleep while reading, watching television, or even while operating a motor vehicle. In addition, embarrassing or inappropriate episodes of sleep (eg, at religious services, while driving) may be reported. Reviewing patient behavior away from the workplace is essential because daytime sleepiness can be masked by activity. Patients should always be asked about behaviors that may mask sleepiness, such as caffeine consumption.",
"   </p>",
"   <p>",
"    Sleepiness is the inability to remain fully awake or alert during the wakefulness portion of the sleep-wake cycle, while fatigue is a subjective lack of physical or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/2\">",
"     2",
"    </a>",
"    ]. It is often unclear whether a patient's complaint of daytime sleepiness represents true sleepiness or fatigue. In such cases, series of directed questions can be combined with the Epworth Sleepiness Scale to quantitatively document the patient&rsquo;s perception of sleepiness, fatigue, or both (",
"    <a class=\"graphic graphic_table graphicRef86812 \" href=\"mobipreview.htm?7/62/8172\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77101 \" href=\"mobipreview.htm?40/20/41291\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2600?source=see_link&amp;anchor=H362471#H362471\">",
"     \"Approach to the patient with excessive daytime sleepiness\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Snoring is the other major feature of OSA. It is usually helpful to have the patient's bed partner or a family member present during the interview because they may have greater insight than the patient into the frequency and severity of the snoring, as well as associated events (ie, resuscitative gasping or snorting, witnessed apneic periods, periods of silence followed by loud snoring, restless or fitful sleep), since these things occur during sleep.",
"   </p>",
"   <p>",
"    In addition to daytime sleepiness and snoring, the clinician should ask about other symptoms and signs that are suggestive of OSA. As an example, sleep maintenance insomnia with repetitive awakenings should prompt consideration of OSA. A small portion of patients with OSA complain of insomnia rather than daytime sleepiness because they are unable to maintain sleep. Other associated symptoms and historical features include the following (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"mobipreview.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Awakening with a sensation of choking, gasping, or smothering",
"     </li>",
"     <li>",
"      Awakening with a dry mouth or sore throat",
"     </li>",
"     <li>",
"      Moodiness or irritability",
"     </li>",
"     <li>",
"      Lack of concentration",
"     </li>",
"     <li>",
"      Memory impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Morning headaches",
"     </li>",
"     <li>",
"      Decreased libido and impotence",
"     </li>",
"     <li>",
"      Awakening with angina pectoris",
"     </li>",
"     <li>",
"      History of hypertension, cardiovascular disease, cerebrovascular disease, or renal disease",
"     </li>",
"     <li>",
"      History of type 2 diabetes mellitus",
"     </li>",
"     <li>",
"      Nocturia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Symptoms of fibromyalgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;OSA is most common among males who are 18 to 60 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/9\">",
"     9",
"    </a>",
"    ], although it is also common at other ages and in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The physical exam is frequently normal, except for obesity (body mass index &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and a crowded oropharyngeal airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/12\">",
"     12",
"    </a>",
"    ]. The obesity may be only moderate, since up to 40 percent of patients are less than 20 percent above their ideal body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional physical findings that are common among patients with OSA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Narrow airway &ndash; Numerous conditions can narrow the upper airway (",
"      <a class=\"graphic graphic_table graphicRef55220 \" href=\"mobipreview.htm?5/4/5195\">",
"       table 4",
"      </a>",
"      ). These include retrognathia, micrognathia, lateral peritonsillar narrowing, macroglossia, tonsillar hypertrophy, an elongated or enlarged uvula, a high arched or narrow palate, nasal septal deviation, and nasal polyps [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large neck",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      waist circumference &ndash; OSA is more strongly correlated with an increased neck size or waist circumference than general obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. OSA is particularly prominent among men who have a collar size greater than 17 inches and women who have a collar size greater than 16 inches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated blood pressure &ndash; Approximately 50 percent of patients with OSA have coexisting hypertension, which is often most elevated in the morning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link&amp;anchor=H2#H2\">",
"       \"Cardiovascular effects of obstructive sleep apnea\", section on 'Systemic hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs of pulmonary hypertension or cor pulmonale (eg, peripheral edema, jugular venous distension) &ndash; Pulmonary hypertension and cor pulmonale are common sequelae when OSA coexists with either obesity hypoventilation syndrome or an alternative cause of daytime hypoxemia (eg, chronic lung disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory data are not helpful in confirming or excluding the diagnosis of OSA. However, nonspecific abnormalities related to OSA are occasionally found in patients being tested for other reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteinuria &ndash; Proteinuria is not common among patients with OSA (&lt;10 percent of patients) but, when it occurs, it may be severe (ie, nephrotic range) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H19#H19\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Severe obesity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercapnia &ndash; Awake hypercapnia is uncommon among patients with OSA alone, but it is often present if obesity hypoventilation syndrome coexists. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38661?source=see_link\">",
"       \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac dysrhythmia &ndash; OSA is associated with nocturnal cardiac dysrhythmias, including bradycardia, atrial fibrillation, and asystole. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism &ndash; Hypothyroidism may cause or exacerbate OSA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations of hypothyroidism\", section on 'Respiratory system'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objective diagnostic testing is necessary because the clinical features of OSA are nonspecific and the diagnostic accuracy of clinical impression alone is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. We recommend that diagnostic testing for OSA be performed on any patient who snores and has excessive daytime sleepiness. In the absence of excessive daytime sleepiness, we recommend diagnostic testing if the patient snores and either works in a mission-critical profession (eg, airline pilots, bus drivers, and truck drivers) or has two or more of the clinical features shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"mobipreview.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    ). This approach is illustrated in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"mobipreview.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ) and assumes that the excessive daytime sleepiness and clinical features are not definitively explained by an alternative etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients selected for diagnostic testing, we suggest full-night (ie, diagnostic only) or split-night (ie, diagnostic and therapeutic), attended, in-laboratory polysomnography. Unattended, in-home portable monitoring is a reasonable alternative for patients without comorbidities and in whom there is a high likelihood of moderate or severe OSA. These diagnostic tests are summarized briefly below and discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Polysomnography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full-night, attended, in-laboratory polysomnography is considered the gold-standard diagnostic test for OSA. It involves monitoring the patient during a full night's sleep. Patients who are diagnosed with OSA and choose positive airway pressure therapy are subsequently brought back for another study, during which their positive airway pressure device is titrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link&amp;anchor=H10#H10\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\", section on 'Determining the amount of positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Split-night, attended, in-laboratory polysomnography is similar, except the diagnostic portion of the study is performed during the first part of the night only. Those patients who are diagnosed with OSA during the first part of the night and choose positive airway pressure therapy can have their positive airway pressure device titrated during the second part of the night.",
"   </p>",
"   <p>",
"    Despite its reputation as the gold-standard, negative in-laboratory polysomnography should be viewed with skepticism if the clinical suspicion of OSA is high. In this situation, repeating the polysomnogram may be worthwhile. This is supported by several studies that have demonstrated significant night-to-night variability in polysomnography results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polysomnography (including technique, measured variables, and derived information) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Portable monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of devices that are used for in-home, unattended, portable monitoring of cardiorespiratory parameters. Many have been validated against standard PSG, typically by testing the same patient with both modalities in the sleep laboratory. Generally speaking, the sensitivity and specificity seem to be high in populations at high risk for OSA on the basis of clinical symptoms, assuming there are no comorbid medical disorders or sleep disorders.",
"   </p>",
"   <p>",
"    We endorse the 2007 clinical practice guidelines from the American Academy of Sleep Medicine (AASM), which indicate that portable monitoring may be used as an alternative to polysomnography for the diagnosis of OSA in patients with a high pre-test probability of moderate to severe OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/24\">",
"     24",
"    </a>",
"    ]. The idea that portable monitoring is a viable alternative to in-laboratory polysomnography in selected individuals is supported by an unblinded trial that randomly assigned 373 patients with suspected moderate to severe OSA to either in-laboratory polysomnography with conventional continuous positive airway pressure (CPAP) titration or portable monitoring with autotitrating CPAP and then transition to fixed CPAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/25\">",
"     25",
"    </a>",
"    ]. Among patients who had moderate to severe OSA (ie, AHI &gt;15 events per hour), there were no differences in the number of effective titrations, titration pressures, time to treatment, or daytime sleepiness. Patients who underwent portable monitoring with autotitrating CPAP were more likely to use CPAP for &ge;4 hours at night.",
"   </p>",
"   <p>",
"    The portable monitoring device must record airflow, respiratory effort, and blood oxygenation, and possibly peripheral arterial tonometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/26\">",
"     26",
"    </a>",
"    ]. Portable monitoring should NOT be used if another sleep disorder is suspected or the patient has comorbid medical conditions that predispose to non-OSA sleep related breathing disorders (eg, heart failure predisposes patients to central sleep apnea).",
"   </p>",
"   <p>",
"    An important limitation of portable monitoring is that it can only detect breathing-related sleep disorders because of the variables that it measures. The use of portable monitoring for adults with suspected OSA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of OSA is based upon the presence or absence of related symptoms, as well as the frequency of respiratory events during sleep (ie, apneas, hypopneas, and respiratory effort related arousals) as measured by polysomnography or portable monitoring. In adults, OSA is confirmed if either of the two conditions exists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are 15 or more apneas, hypopneas, or respiratory effort related arousals per hour of sleep (ie, an apnea hypopnea index or respiratory disturbance index &ge;15 events per hour) in an asymptomatic patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/27\">",
"       27",
"      </a>",
"      ]. More than 75 percent of the apneas and hypopneas must be obstructive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/28\">",
"       28",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      There are five or more obstructive apneas, obstructive hypopneas, or respiratory effort related arousals per hour of sleep (ie, an apnea hypopnea index or respiratory disturbance index &ge;5 events per hour) in a patient with symptoms or signs of disturbed sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/27\">",
"       27",
"      </a>",
"      ]. More than 75 percent of the apneas and hypopneas must be obstructive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the apnea hypopnea index or the respiratory disturbance index should be the gold standard index remains unclear and varies across insurance carriers. Outcome studies are needed to achieve a consensus regarding which index is preferred. &nbsp;",
"   </p>",
"   <p>",
"    Apneas, hypopneas, respiratory effort related arousals, apnea hypopnea index, and respiratory disturbance index are defined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13336630\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions must be considered in the differential diagnosis of OSA because they similarly cause excessive daytime sleepiness due to disrupted sleep (",
"    <a class=\"graphic graphic_table graphicRef86811 \" href=\"mobipreview.htm?18/3/18493\">",
"     table 5",
"    </a>",
"    ). These conditions can be distinguished from OSA via polysomnography:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Periodic limb movements of sleep &ndash; Periodic limb movements of sleep (PLMS) are recurrent jerks of the legs and arms that can fragment sleep, leading to daytime sleepiness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotating shift workers &ndash; Night-shift workers obtain approximately seven hours per week less sleep than non-shift workers. They often revert to a daytime schedule on their leisure days, which adds to their sleep deprivation and daytime sleepiness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link&amp;anchor=H6#H6\">",
"       \"Types of insomnia\", section on 'Shift work'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narcolepsy &ndash; Narcolepsy is a clinical syndrome of excess daytime sleepiness with cataplexy, hypnagogic hallucinations, and sleep paralysis. &ldquo;Sleep attacks&rdquo; are classically described, although there is a wide spectrum of clinical presentations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=see_link\">",
"       \"Clinical features and diagnosis of narcolepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper airway resistance syndrome &ndash; Upper airway resistance syndrome (UARS) was previously classified as an independent disorder, but it is now considered a type of OSA according to the most recent International Classification of Sleep Disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/30\">",
"       30",
"      </a>",
"      ]. It exists when airflow limitation due to increased upper airway resistance (ie, respiratory effort related arousals [RERAs]) induces arousals from sleep, leading to excessive daytime sleepiness. Patients with UARS have few discrete respiratory disturbances (ie, apneas or hypopneas) or episodes of desaturation. It is common in thin women with certain craniofacial abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H19#H19\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Upper airways resistance syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central sleep apneas &ndash; Central sleep apnea is less common than OSA, but it similarly causes symptoms of disrupted sleep due to episodic apneas and hypopneas during sleep. The primary difference between OSA and central sleep apnea is that respiratory effort is present in the former but not the latter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=see_link\">",
"       \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory diseases &ndash; Patients with either chronic obstructive lung disease or restrictive lung disease may have sleep-related desaturation, resulting in sudden awakenings and dyspnea that imitate OSA. Patients with neuromuscular disease depend on their accessory muscles to breathe and the inhibition of muscle activity during REM sleep can cause profound desaturations and awakenings. Poorly controlled asthma is often worse at night, with nocturnal bronchospasm and cough inducing sleep fragmentation and paroxysmal dyspnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are conditions that should be considered in the differential diagnosis of OSA because they similarly cause abrupt awakenings or abnormal sounds or sensations during sleep (",
"    <a class=\"graphic graphic_table graphicRef50784 \" href=\"mobipreview.htm?4/43/4795\">",
"     table 6",
"    </a>",
"    ). These conditions can be distinguished from OSA via polysomnography:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary snoring &ndash; Snoring is far more common than OSA. Therefore, even though most patients who have OSA snore, most patients who snore do not have OSA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22022?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of snoring in adults\", section on 'Diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease &ndash; Gastroesophageal reflux disease (GERD) can mimic OSA by producing a choking sensation and dyspnea. In addition, GERD may improve with positive airway pressure therapy, further mimicking OSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41607/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Miscellaneous &ndash; Other disorders that can mimic OSA include swallowing disorders, nocturnal seizures, and psychiatric illnesses such as panic attacks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas and hypopneas caused by repetitive collapse of the upper airway during sleep. OSA should be considered whenever a patient presents with risk factors or clinical manifestations that are compatible with OSA. The challenge is to select patients who are most likely to have OSA for further diagnostic evaluation, since expensive and time consuming testing is required to identify OSA. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with OSA first come to the attention of a clinician because the patient complains of daytime sleepiness, or the bed partner reports loud snoring, gasping, or snorting during sleep. Patients with any of these complaints should be asked about and examined for other features of OSA. This information is important for determining which patients require diagnostic testing.",
"     </li>",
"     <li>",
"      Diagnostic testing is indicated in any patient who snores and has excessive daytime sleepiness. In the absence of excessive daytime sleepiness, we recommend diagnostic testing if the patient snores and either has two or more of the features shown in the table (",
"      <a class=\"graphic graphic_table graphicRef55633 \" href=\"mobipreview.htm?12/10/12460\">",
"       table 1",
"      </a>",
"      ) or works in a mission-critical profession (eg, airline pilots, bus and truck drivers). This approach is illustrated in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"mobipreview.htm?22/5/22622\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest full-night or split-night, attended, in-laboratory polysomnography. Unattended, in-home portable monitoring is a reasonable alternative for patients in whom there is a high likelihood that they have moderate or severe OSA and who have no comorbidities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of OSA is based upon the presence or absence of related symptoms, as well as the frequency of apneas, hypopneas, and respiratory effort related arousals during sleep. OSA is confirmed if either of the two conditions exists (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are 15 or more apneas, hypopneas, or respiratory effort related arousals per hour of sleep (ie, an apnea hypopnea index or respiratory disturbance index &ge;15 events per hour) in an asymptomatic patient. More than 75 percent of the apneas and hypopneas must be obstructive.",
"     </li>",
"     <li>",
"      There are five or more obstructive apneas, obstructive hypopneas, or respiratory effort related arousals per hour of sleep (ie, an apnea hypopnea index or respiratory disturbance index &ge;5 events per hour) in a patient with symptoms or signs of disturbed sleep. More than 75 percent of the apneas and hypopneas must be obstructive.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/1\">",
"      Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest 2000; 118:372.",
"     </a>",
"    </li>",
"    <li>",
"     Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC, Paralyzed Veterans of America, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/3\">",
"      Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/4\">",
"      Hossain JL, Ahmad P, Reinish LW, et al. Subjective fatigue and subjective sleepiness: two independent consequences of sleep disorders? J Sleep Res 2005; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/5\">",
"      Wallace A, Bucks RS. Memory and obstructive sleep apnea: a meta-analysis. Sleep 2013; 36:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/6\">",
"      Margel D, Shochat T, Getzler O, et al. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 2006; 67:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/7\">",
"      Wheaton AG, Perry GS, Chapman DP, Croft JB. Sleep disordered breathing and depression among U.S. adults: National Health and Nutrition Examination Survey, 2005-2008. Sleep 2012; 35:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/8\">",
"      Shah MA, Feinberg S, Krishnan E. Sleep-disordered breathing among women with fibromyalgia syndrome. J Clin Rheumatol 2006; 12:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/9\">",
"      Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/10\">",
"      Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/11\">",
"      Bixler EO, Vgontzas AN, Ten Have T, et al. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 1998; 157:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/12\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/13\">",
"      Kales A, Cadieux RJ, Bixler EO, et al. Severe obstructive sleep apnea--I: Onset, clinical course, and characteristics. J Chronic Dis 1985; 38:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/14\">",
"      Stradling JR, Crosby JH. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax 1991; 46:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/15\">",
"      Carmelli D, Swan GE, Bliwise DL. Relationship of 30-year changes in obesity to sleep-disordered breathing in the Western Collaborative Group Study. Obes Res 2000; 8:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/16\">",
"      Sajkov D, Cowie RJ, Thornton AT, et al. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994; 149:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/17\">",
"      Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/18\">",
"      Chaudhary BA, Rehman OU, Brown TM. Proteinuria in patients with sleep apnea. J Fam Pract 1995; 40:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/19\">",
"      Viner S, Szalai JP, Hoffstein V. Are history and physical examination a good screening test for sleep apnea? Ann Intern Med 1991; 115:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/20\">",
"      Hoffstein V, Szalai JP. Predictive value of clinical features in diagnosing obstructive sleep apnea. Sleep 1993; 16:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/21\">",
"      Meyer TJ, Eveloff SE, Kline LR, Millman RP. One negative polysomnogram does not exclude obstructive sleep apnea. Chest 1993; 103:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/22\">",
"      Ahmadi N, Shapiro GK, Chung SA, Shapiro CM. Clinical diagnosis of sleep apnea based on single night of polysomnography vs. two nights of polysomnography. Sleep Breath 2009; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/23\">",
"      Levendowski DJ, Zack N, Rao S, et al. Assessment of the test-retest reliability of laboratory polysomnography. Sleep Breath 2009; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/24\">",
"      Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007; 3:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/25\">",
"      Rosen CL, Auckley D, Benca R, et al. A multisite randomized trial of portable sleep studies and positive airway pressure autotitration versus laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: the HomePAP study. Sleep 2012; 35:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/26\">",
"      Collop NA, Tracy SL, Kapur V, et al. Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. J Clin Sleep Med 2011; 7:531.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/28\">",
"      Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev 2010; 90:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/29\">",
"      Black JE, Brooks SN, Nishino S. Conditions of primary excessive daytime sleepiness. Neurol Clin 2005; 23:1025.",
"     </a>",
"    </li>",
"    <li>",
"     The International Classification of Sleep Disorders, 2nd edition, Diagnostic and Coding Manual, 2nd ed, Hauri PJ (Ed), American Academy of Sleep Medicine, Westchester 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/31\">",
"      Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/32\">",
"      Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med 1995; 122:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41607/abstract/33\">",
"      Tawk M, Goodrich S, Kinasewitz G, Orr W. The effect of 1 week of continuous positive airway pressure treatment in obstructive sleep apnea patients with concomitant gastroesophageal reflux. Chest 2006; 130:1003.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7706 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41607=[""].join("\n");
var outline_f40_40_41607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13336404\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS FOR DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Polysomnography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Portable monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13336630\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7706|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/5/22622\" title=\"algorithm 1\">",
"      OSA diagnosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/10/12460\" title=\"table 1\">",
"      Clinical features OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/62/8172\" title=\"table 2\">",
"      Key questions for tired patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/20/41291\" title=\"table 3\">",
"      Epworth sleepiness scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/4/5195\" title=\"table 4\">",
"      Increased upper airway resist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/3/18493\" title=\"table 5\">",
"      Differential diagnosis of excessive daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/43/4795\" title=\"table 6\">",
"      Disorders that mimic OSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2600?source=related_link\">",
"      Approach to the patient with excessive daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22022?source=related_link\">",
"      Overview of snoring in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41608="Microbiology, epidemiology and treatment of Haemophilus influenzae";
var content_f40_40_41608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, epidemiology and treatment of Haemophilus influenzae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Sylvia Yeh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41608/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/40/41608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae colonizes the human respiratory tract and is transmitted from person to person via airborne droplets and direct contact with respiratory secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    H. influenzae has encapsulated (serotypes a through f) and non-encapsulated forms (nontypeable). The most important serotype is H. influenzae serotype b (Hib), which was a frequent cause of bacteremia, meningitis, and other invasive infections prior to the routine use of Hib conjugate vaccines in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/2\">",
"     2",
"    </a>",
"    ]. Other capsular serotypes and unencapsulated H. influenzae strains can also cause disease, mainly mucosal infections (sinusitis, otitis, bronchitis and pneumonia) but occasionally cause more invasive infections.",
"   </p>",
"   <p>",
"    The bacteriology, epidemiology, and treatment of H. influenzae are reviewed here. H. influenzae infections in children and prevention of H. influenzae are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link\">",
"     \"Prevention of Haemophilus influenzae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. influenzae are small, pleomorphic gram-negative rods that are oxidase-positive, facultatively anaerobic, and nonmotile. In clinical specimens obtained from patients who have received beta-lactam antibiotics, H. influenzae can appear as filamentous rods. In vitro growth requires a CO2-enriched atmosphere,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    (factor X), and nicotinamide adenine dinucleotide (NAD, factor V); therefore, isolation from clinical specimens on solid medium requires the use of chocolate agar or other X and V factor supplemented media. H. influenzae appear as transparent or slightly opaque colonies on solid media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of a polysaccharide capsule is an important distinguishing characteristic of H. influenzae species. The polysaccharide capsule can be serologically classified into six serotypes (a through f), while H. influenzae lacking a polysaccharide capsule are considered to be nontypeable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/3\">",
"     3",
"    </a>",
"    ]. The type b capsule consists of a ribosyl and ribitol phosphate polymer and is the primary antigenic constituent of polysaccharide and polysaccharide conjugate Hib vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nontypeable strains are genetically heterogeneous; some carry genetic elements for capsule production that are not expressed, while other isolates do not have any of these genes and are more distantly related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/3\">",
"     3",
"    </a>",
"    ]. Even among identically classified nontypeable strains, electrophoresis of outer membrane proteins or enzymatic analysis demonstrates great heterogeneity of nonencapsulated strains.",
"   </p>",
"   <p>",
"    Infections of the upper and lower respiratory tract are largely caused by nontypeable strains. Nontypeable strains have been classified into eight biotypes based upon the presence or absence of indole, urease, and ornithine decarboxylase. Some biotypes have been associated with specific clinical syndromes; H. influenzae biotype 3 isolates (also known as biotype aegyptius) are associated with the syndrome of Brazilian purpuric fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/4\">",
"     4",
"    </a>",
"    ], and biotype 4 isolates are associated with maternal genitourinary tract infections and neonatal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Outer membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outer membrane of H. influenzae contains several proteins enabling attachment to epithelial cells and facilitating colonization of the human respiratory tract. These include pili, fimbriae, high molecular weight factors (HMW1 and HMW2), and Hia (homologous to the pertussis hemagglutinin). Pili seem to be required for adherence to respiratory mucin and pharyngeal colonization, while the other adhesins may be more influential in the pathogenesis of otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. A study of strains lacking the pili structural genes (hifA) demonstrated diminished bacterial adherence to mucin; antibodies to hifA also blocked adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/9\">",
"     9",
"    </a>",
"    ]. In a report of 17 nasopharyngeal and middle ear isolates, most expressed HMW1 or HMW2, while only a few nasopharyngeal isolates expressed pili or Hia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lipopolysaccharide (LPS) is also a component of the H. influenzae outer membrane that contributes to pathogen structural integrity and elicits a potent endotoxin host inflammatory response. Hib LPS has limited antigenic diversity, although variability in LPS electrophoretic patterns occurs with passage in vivo or in vitro, making electrophoresis of LPS a less useful epidemiologic tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/11\">",
"     11",
"    </a>",
"    ]. When injected, Hib LPS produces a dermal Shwartzman reaction, is lethal in mice, causes a febrile response, and evokes polyclonal B-cell activation in rabbits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     IgA proteases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the important role of IgA in mucosal defense, bacterial IgA proteases are likely important virulence factors. H. influenzae produces three types of IgA proteases that cleave different peptide bonds within the IgA1 hinge region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intracellular survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. influenzae can survive within respiratory epithelial cells; this intracellular sequestration may explain the ability of these organisms to colonize the respiratory epithelium for extended periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, H. influenzae can gain access to the subepithelial space, either by transmural migration across epithelial cells, or by an independent intercellular mechanism. This provides access to the vascular system, which can lead to bacteremia and metastatic infection, including meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;By 18 months of age, one-third of children have had H. influenzae nasopharyngeal colonization with both typeable and nontypeable H. influenzae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. Carriage rates in households or day care centers with an index case can exceed 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Colonization can persist for months, and intercurrent upper respiratory infection may promote invasive disease as well as enhance spread among close contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/9,15,17-19\">",
"     9,15,17-19",
"    </a>",
"    ]. Simultaneous colonization by multiple strains is common, and longitudinal monitoring demonstrates that colonization is a dynamic process, with a turnover of individual strains over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the introduction of Hib conjugate vaccines in 1985, the incidence of invasive disease cause by H. influenzae in the United States has decreased dramatically. Between 1989 and 2008, 7559 cases of H. influenzae disease were reported in the United States; the estimated mean annual incidence was 1.62 per 100,000 population and 15 percent of cases were fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/20\">",
"     20",
"    </a>",
"    ]. A considerable burden of non-Hib disease is still present in the oldest and youngest age groups. The largest burden of disease among children occurred in infants &lt;1 year; many of these cases occurred during the first month of life in preterm or low-birth weight infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     H. influenzae serotype b",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. influenzae is an exclusively human pathogen; it is transmitted from person to person via airborne droplets and direct contact with respiratory secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/1\">",
"     1",
"    </a>",
"    ]. Prior to the routine use of H. influenzae serotype b (Hib) conjugate vaccines in infants, invasive Hib was the leading cause of bacterial meningitis in children; 85 percent of these infections occurred in children under five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/21\">",
"     21",
"    </a>",
"    ]. Hib was also a leading cause of epiglottitis, pneumonia, empyema, pericarditis, bacteremia, and septic arthritis. Clinical manifestations of invasive Hib infections reflect the organism's capacity for vascular invasion and establishing metastatic foci of infection including meningitis, septic arthritis, osteomyelitis and cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to routine vaccination, the incidence of invasive Hib disease varied from 67 to 130 cases per 100,000 children under five years per year, and the incidence of Hib meningitis was 40 to 69 cases per 100,000 children per year. This incidence was equivalent to approximately 25,000 cases of acquired invasive Hib annually in the United States, or invasive infection in 1 per 200 children in the first five years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/22\">",
"     22",
"    </a>",
"    ]. Some populations at increased risk had incidence up to four times this rate.",
"   </p>",
"   <p>",
"    Before widespread immunization, the secondary attack rate among children who were household contacts of an index case was 0.3 percent, which is 500-fold higher than the age-adjusted risk in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/19\">",
"     19",
"    </a>",
"    ]. This risk of secondary infection increased inversely with age; children under four years of age were at greatest risk, and clinical disease was most likely in the first 30 days after exposure to the index case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/23-29\">",
"     23-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the widespread use of conjugate Hib vaccines in infancy has resulted in a dramatic decline in invasive Hib disease in children to one case or less per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. The incidence of invasive disease among individuals over five years of age has been stable at approximately 0.5 per 100,000 population.",
"   </p>",
"   <p>",
"    Hib immunization has reduced carriage (and presumably transmission) and facilitated herd immunity. This reduction in carriage seems to be influenced by number and type of Hib immunizations as well as time post immunization. Consequently, the differences in immunization schedules internationally may result in differing carriage and disease patterns. In England, following a period of time when only infant Hib vaccination was practiced (without a toddler booster), there was waning immunity and some recurrence of Hib disease among toddlers. Investigators found that the point prevalence of Hib carriage among 855 British children ages 6 to 16 during this period (between 1999 and 2003) remained high (4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The global burden of Hib disease is substantial; worldwide Hib caused about 8.13 million serious illnesses worldwide in 2000, with 371,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/32\">",
"     32",
"    </a>",
"    ]. This is almost entirely vaccine preventable; expanded use of the Hib vaccine could reduce pneumonia, meningitis and mortality among children.",
"   </p>",
"   <p>",
"    Most cases of invasive H. influenzae infection since introduction of the Hib vaccination have been attributable to non-type B strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/21,33\">",
"     21,33",
"    </a>",
"    ]. Some reports of invasive H. influenzae from areas with widespread Hib conjugate vaccination have identified serotype f and nontypable H. influenzae as being the most common of the invasive isolates, with one series reporting serotype a predominately in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Children who experience Hib disease despite vaccination may have an immunologic defect impairing production of memory B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nontypeable H. influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontypeable H. influenzae (NTHi) is a common commensal constituent of the nasopharyngeal flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Approximately 20 percent of infants are colonized in the first year of life, and more than one-half of children are colonized by age five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/40\">",
"     40",
"    </a>",
"    ]. Children may be colonized by multiple distinct strains at a given time, and colonizing strains may change over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Colonization persists throughout adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/40,44,45\">",
"     40,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NTHi causes noninvasive infections in older children and adults, usually as a result of local spread of organisms from the nasopharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/46\">",
"     46",
"    </a>",
"    ]. It is an important cause of sinusitis, otitis media, conjunctivitis, bronchitis, pneumonia and bacteremia and posttraumatic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/3,5,18,47-53\">",
"     3,5,18,47-53",
"    </a>",
"    ]. In a report of 157 cases of otitis media, for example, NTHi accounted for about 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/53\">",
"     53",
"    </a>",
"    ]. The density of NTHi colonization has been correlated with increased rates of otitis media, although no correlation has been established between the duration of NTHi colonization and the risk of otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTHi can cause community-acquired pneumonia in adults and may be associated with severe disease and high mortality in higher risk populations. Although bacteremia that complicates H. influenzae pneumonia occurs occasionally, disseminated infections following nontypeable H. influenzae bacteremia are uncommon, except in newborns and immunocompromised patients.",
"   </p>",
"   <p>",
"    Nontypeable H. influenzae can also colonize the female genital tract and cause locally invasive disease such as endometritis, amnionitis, or Bartholin gland abscess, with or without accompanying bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to age, factors conferring increased risk for H. influenzae infection include underlying immunocompromising conditions including complement deficiency, hypogammaglobulinemia, sickle cell anemia, functional asplenia, malignancy and HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/16,19,56-60\">",
"     16,19,56-60",
"    </a>",
"    ]. In adults, underlying conditions such as chronic pulmonary disease, smoking, HIV, alcoholism, pregnancy, malignancy, and older age increase the risk of H. influenzae disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. Socioeconomic risk factors that increase risk include crowding, poor immunization, and day care attendance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/19,56,67\">",
"     19,56,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Native American and aboriginal groups are also at increased risk for invasive H. influenzae disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/58,68\">",
"     58,68",
"    </a>",
"    ]. In an Australian review of bacterial meningitis, for example, the annual incidence rate of H. influenzae was significantly higher in Aboriginal than non-Aboriginal children (150 versus 27 per 100,000 persons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/58\">",
"     58",
"    </a>",
"    ]. Socioeconomic, environmental, microbiologic, and genetic factors may play an important role in these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both innate and acquired humoral immunity play important roles in host defense against invasive H. influenzae. Newborns are protected against Hib via maternal antibodies, but they are susceptible to infection with nontypeable (unencapsulated) strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/51\">",
"     51",
"    </a>",
"    ]. Breast feeding affords some protection against H. influenzae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/57\">",
"     57",
"    </a>",
"    ]. As maternal antibody levels wane, children become susceptible to invasive Hib infection from around age three months to three years.",
"   </p>",
"   <p>",
"    Prior to the routine use of Hib conjugate vaccines, children older than three years of age progressively gained protection against invasive disease with repeated exposure and subsequent nasopharyngeal colonization. The decline in individual serum anti-Hib antibody levels observed since introduction of Hib vaccination suggests that ongoing antigen exposure in the setting of Hib colonization may play a role Hib immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The opsonization of H. influenzae by C3 and subsequent phagocytosis appears to be more important than direct complement-mediated lysis. This understanding is based upon the clinical observation that individuals with deficiencies of early complement components are at increased risk for H. influenzae infections, while those with deficiencies of terminal complement components do not experience heightened susceptibility to the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/69\">",
"     69",
"    </a>",
"    ]. H. influenzae lipooligosaccharide (LOS) activates the alternative complement pathway to generate C3b, an important opsonin. Anticapsular antibodies, particularly of the IgG1 subclass, bind to the polysaccharide capsule and activate the classical complement pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of specific syndromes attributable to H. influenzae is discussed in detail separately. In general, beta-lactam agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or a second- or third-generation cephalosporin) are the preferred antimicrobial agents if the organism is susceptible (",
"    <a class=\"graphic graphic_table graphicRef64816 \" href=\"mobipreview.htm?19/63/20478\">",
"     table 1",
"    </a>",
"    ). Alternative agents with activity against H. influenzae include fluoroquinolones, macrolides, tetracyclines, and aminoglycosides. Among the macrolides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is more active in vitro against most strains of H. influenzae and has more rapid killing and a longer post-antibiotic effect than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Haemophilus influenzae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'H. influenzae type b'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053902952\">",
"    <span class=\"h2\">",
"     BLNAR and beta-lactam-resistant H. influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactamase-negative,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    -resistant (BLNAR) H. influenzae is an emerging pathogen. The prevalence of BLNAR H. influenzae strains has increased in Japan (approximately 34 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/48\">",
"     48",
"    </a>",
"    ] and Spain (approximately 56 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/49\">",
"     49",
"    </a>",
"    ], and other parts of Europe and Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/72\">",
"     72",
"    </a>",
"    ]. Prevalence in the United States has remained low (approximately 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/50\">",
"     50",
"    </a>",
"    ]. Possible explanations for this observation include inadequate vaccination against H. influenzae type b in some regions, increasingly frequent use of cephalosporins, and underdosing of oral ampicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. There are no significant differences in the clinical presentation of pneumonia due to BLNAR H. influenzae compared to pneumonia due to ampicillin-susceptible H. influenzae strains.",
"   </p>",
"   <p>",
"    These pathogens appear to be susceptible in vitro to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/73\">",
"     73",
"    </a>",
"    ]. Depending on local susceptibility findings, ceftriaxone may be an appropriate choice for treatment of clinical infections due to BLNAR H. influenzae pending further study of clinical infections with this pathogen.",
"   </p>",
"   <p>",
"    There have also been reports of increased prevalence of non-typeable H. influenzae strains with resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other beta-lactams. In a retrospective study that evaluated 465 H. influenzae isolates from the blood or cerebrospinal fluid from patients in Sweden between 1997 and 2010, a significant increase in beta-lactamase negative, beta-lactam-resistant isolates was observed over the course of the study period. Ninety-one isolates (20 percent) were beta-lactam resistant (defined as resistance to one or more beta-lactam, including penicillin, ampicillin, a cephalosporin, or a carbapenem), of which 43 (10 percent) were beta-lactamase negative and beta-lactam-resistant. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41608/abstract/74\">",
"     74",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053902167\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Haemophilus influenzae colonizes the human respiratory tract and is transmitted from person to person via airborne droplets and direct contact with respiratory secretions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      H. influenzae are small, pleomorphic gram-negative rods that are oxidase-positive, facultatively anaerobic, and nonmotile. The presence or absence of a polysaccharide capsule is an important distinguishing characteristic of H. influenzae species. The polysaccharide capsule can be serologically classified into six serotypes (a through f), while H. influenzae lacking a polysaccharide capsule are considered to be nontypeable. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      By 18 months of age, one-third of children have had H. influenzae nasopharyngeal colonization with both typeable and nontypeable H. influenzae. Carriage rates in households or day care centers with an index case can exceed 60 percent. Colonization can persist for months, and intercurrent upper respiratory infection may promote invasive disease as well as enhance spread among close contacts. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the routine use of H. influenzae serotype b (Hib) conjugate vaccines in infants, invasive Hib was the leading cause of bacterial meningitis in children; 85 percent of these infections occurred in children under five years of age. Hib was also a leading cause of epiglottitis, pneumonia, empyema, pericarditis, bacteremia, and septic arthritis. Clinical manifestations of invasive Hib infections reflect the organism's capacity for vascular invasion and establishing metastatic foci of infection including meningitis, septic arthritis, osteomyelitis, and cellulitis. Most cases of invasive H. influenzae infection since introduction of the Hib vaccination have been attributable to non-type B strains. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'H. influenzae serotype b'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontypeable H. influenzae can cause community-acquired pneumonia in adults and may be associated with severe disease and high mortality in higher risk populations. Although bacteremia that complicates H. influenzae pneumonia occurs occasionally, disseminated infections following nontypeable H. influenzae bacteremia are uncommon, except in newborns and immunocompromised patients. Nontypeable H. influenzae can also colonize the female genital tract and cause locally invasive disease, such as endometritis, amnionitis, or Bartholin gland abscess, with or without accompanying bacteremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nontypeable H. influenzae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to age, factors conferring increased risk for H. influenzae infection include underlying immunocompromising conditions, including complement deficiency, hypogammaglobulinemia, sickle cell anemia, functional asplenia, malignancy, and HIV. In adults, underlying conditions, such as chronic pulmonary disease, smoking, HIV, alcoholism, pregnancy, malignancy, and older age, increase the risk of H. influenzae disease. Socioeconomic risk factors that increase risk include crowding, poor immunization, and day care attendance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of specific syndromes attributable to H. influenzae is discussed in detail separately. In general, beta-lactam agents (eg, penicillins, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , or second or third-generation cephalosporins) are the preferred antimicrobial agents if the organism is susceptible (",
"      <a class=\"graphic graphic_table graphicRef64816 \" href=\"mobipreview.htm?19/63/20478\">",
"       table 1",
"      </a>",
"      ). Alternative agents with activity against H. influenzae include fluoroquinolones, macrolides, tetracyclines, and aminoglycosides. Among the macrolides,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      is more active in vitro against most strains of H. influenzae than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Haemophilus influenzae'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H28#H28\">",
"       \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'H. influenzae type b'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta-lactamase-negative,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      -resistant (BLNAR) H. influenzae is an emerging pathogen in certain regions, such as Japan and Spain, although its prevalence in the United States and elsewhere remains low. These pathogens appear to be susceptible in vitro to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      . There have also been reports of increased prevalence of non-typeable H. influenzae strains with resistance to ampicillin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other beta-lactams. (See",
"      <a class=\"local\" href=\"#H1053902952\">",
"       'BLNAR and beta-lactam-resistant H. influenzae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Vaccines, 3, Plotkin SA, Orienstein WA (Eds), WB Saunders Company, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/2\">",
"      Eskola J, K&auml;yhty H, Takala AK, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/3\">",
"      St Geme JW 3rd, Takala A, Esko E, Falkow S. Evidence for capsule gene sequences among pharyngeal isolates of nontypeable Haemophilus influenzae. J Infect Dis 1994; 169:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/4\">",
"      Segada LM, Carlone GM, Gheesling LL, Lesse AJ. Characterization of P1-deficient isogenic mutant of Haemophilus influenzae biogroup aegyptius associated with Brazilian purpuric fever. Microb Pathog 2000; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/5\">",
"      Quentin R, Musser JM, Mellouet M, et al. Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV. J Clin Microbiol 1989; 27:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/6\">",
"      Wallace RJ Jr, Baker CJ, Quinones FJ, et al. Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis 1983; 5:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/7\">",
"      Rao VK, Krasan GP, Hendrixson DR, et al. Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. FEMS Microbiol Rev 1999; 23:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/8\">",
"      Krasan GP, Cutter D, Block SL, St Geme JW 3rd. Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media. Infect Immun 1999; 67:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/9\">",
"      Kubiet M, Ramphal R, Weber A, Smith A. Pilus-mediated adherence of Haemophilus influenzae to human respiratory mucins. Infect Immun 2000; 68:3362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/10\">",
"      St Geme JW 3rd. Insights into the mechanism of respiratory tract colonization by nontypable Haemophilus influenzae. Pediatr Infect Dis J 1997; 16:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/11\">",
"      Whisnant JK, Rogentine GN, Mann DL, Robbins JB. Human cell-surface structures related to Haemophilus influenzae type B disease. Lancet 1971; 2:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/12\">",
"      Miragliotta G, Colucci M, Semeraro N, et al. Platelet injury and stimulation of leukocyte procoagulant activity in vitro by a lipopolysaccharide from Haemophilus influenzae type b. Microbiologica 1981; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/13\">",
"      Plaut AG. The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol 1983; 37:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/14\">",
"      Moxon ER. Molecular basis of invasive Haemophilus influenzae type b disease. J Infect Dis 1992; 165 Suppl 1:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/15\">",
"      Aniansson G, Alm B, Andersson B, et al. Nasopharyngeal colonization during the first year of life. J Infect Dis 1992; 165 Suppl 1:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/16\">",
"      Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev 1991; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/17\">",
"      Krasinski K, Nelson JD, Butler S, et al. Possible association of mycoplasma and viral respiratory infections with bacterial meningitis. Am J Epidemiol 1987; 125:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/18\">",
"      Takala AK, Meurman O, Kleemola M, et al. Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J 1993; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/19\">",
"      M&auml;kel&auml; PH, Takala AK, Peltola H, Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992; 165 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/20\">",
"      MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. Clin Infect Dis 2011; 53:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/21\">",
"      Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990; 162:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/22\">",
"      Cochi SL, Broome CV. Vaccine prevention of Haemophilus influenzae type b disease: past, present and future. Pediatr Infect Dis 1986; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/23\">",
"      Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 1979; 301:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/24\">",
"      Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/25\">",
"      Band JD, Fraser DW, Ajello G. Prevention of Hemophilus influenzae type b disease. JAMA 1984; 251:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/26\">",
"      Fleming DW, Leibenhaut MH, Albanes D, et al. Secondary Haemophilus influenzae type b in day-care facilities. Risk factors and prevention. JAMA 1985; 254:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/27\">",
"      Makintubee S, Istre GR, Ward JI. Transmission of invasive Haemophilus influenzae type b disease in day care settings. J Pediatr 1987; 111:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/28\">",
"      Osterholm MT, Pierson LM, White KE, et al. The risk of subsequent transmission of Hemophilus influenzae type B disease among children in day care. Results of a two-year statewide prospective surveillance and contact survey. N Engl J Med 1987; 316:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/29\">",
"      Murphy TV, Clements JF, Breedlove JA, et al. Risk of subsequent disease among day-care contacts of patients with systemic Hemophilus influenzae type B disease. N Engl J Med 1987; 316:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/31\">",
"      Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/32\">",
"      Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/33\">",
"      Heath PT, Booy R, Azzopardi HJ, et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 2001; 20:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/34\">",
"      Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010; 28:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/35\">",
"      Bender JM, Cox CM, Mottice S, et al. Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine. Clin Infect Dis 2010; 50:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/36\">",
"      Resman F, Ristovski M, Ahl J, et al. Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. Clin Microbiol Infect 2011; 17:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/37\">",
"      Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/38\">",
"      St Geme JW 3rd. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion. Cell Microbiol 2002; 4:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/39\">",
"      Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/40\">",
"      Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiol Infect 1988; 100:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/41\">",
"      Spinola SM, Peacock J, Denny FW, et al. Epidemiology of colonization by nontypable Haemophilus influenzae in children: a longitudinal study. J Infect Dis 1986; 154:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/42\">",
"      Trottier S, Stenberg K, Svanborg-Ed&eacute;n C. Turnover of nontypable Haemophilus influenzae in the nasopharynges of healthy children. J Clin Microbiol 1989; 27:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/43\">",
"      Faden H, Duffy L, Williams A, et al. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 1995; 172:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/44\">",
"      Faden H, Waz MJ, Bernstein JM, et al. Nasopharyngeal flora in the first three years of life in normal and otitis-prone children. Ann Otol Rhinol Laryngol 1991; 100:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/45\">",
"      Kuklinska D, Kilian M. Relative proportions of Haemophilus species in the throat of healthy children and adults. Eur J Clin Microbiol 1984; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/46\">",
"      Farley MM, Stephens DS, Brachman PS Jr, et al. Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 1992; 116:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/47\">",
"      S&aacute;ez-Llorens X. Pathogenesis of acute otitis media. Pediatr Infect Dis J 1994; 13:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/48\">",
"      Hasegawa K, Kobayashi R, Takada E, et al. High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced. J Antimicrob Chemother 2006; 57:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/49\">",
"      Garc&iacute;a-Cobos S, Campos J, L&aacute;zaro E, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 2007; 51:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/50\">",
"      Nakamura S, Yanagihara K, Seki M, et al. Clinical characteristics of pneumonia caused by beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR). Scand J Infect Dis 2007; 39:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/51\">",
"      Falla TJ, Dobson SR, Crook DW, et al. Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates. Lancet 1993; 341:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/52\">",
"      Winkelstein JA, Moxon ER. The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 1992; 165 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/53\">",
"      Harabuchi Y, Faden H, Yamanaka N, et al. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Tonawanda/Williamsville Pediatrics. J Infect Dis 1994; 170:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/54\">",
"      Faden H, Stanievich J, Brodsky L, et al. Changes in nasopharyngeal flora during otitis media of childhood. Pediatr Infect Dis J 1990; 9:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/55\">",
"      Long SS, Henretig FM, Teter MJ, McGowan KL. Nasopharyngeal flora and acute otitis media. Infect Immun 1983; 41:987.",
"     </a>",
"    </li>",
"    <li>",
"     Michaels RH, Schultz WF. The frequency of Haemophilus influenzae infections: Analysis of racial and environmental factors. In: Haemophilus influenzae, Sell SH, Karson DT (Eds), Vanderbilt University Press, Nashville 1973. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/57\">",
"      Petersen GM, Silimperi DR, Chiu CY, Ward JI. Effects of age, breast feeding, and household structure on Haemophilus influenzae type b disease risk and antibody acquisition in Alaskan Eskimos. Am J Epidemiol 1991; 134:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/58\">",
"      Hanna JN, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. Med J Aust 1991; 155:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/59\">",
"      Mu&ntilde;oz P, Miranda ME, Llancaqueo A, et al. Haemophilus species bacteremia in adults. The importance of the human immunodeficiency virus epidemic. Arch Intern Med 1997; 157:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/60\">",
"      Cordero E, Pach&oacute;n J, Rivero A, et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Clin Infect Dis 2000; 30:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/61\">",
"      M&ouml;ller LV, Regelink AG, Grasselier H, et al. Multiple Haemophilus influenzae strains and strain variants coexist in the respiratory tract of patients with cystic fibrosis. J Infect Dis 1995; 172:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/62\">",
"      Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in children with sickle cell anemia? Pediatrics 1983; 71:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/63\">",
"      Chilcote RR, Baehner RL, Hammond D. Septicemia and meningitis in children splenectomized for hodgkin's disease. N Engl J Med 1976; 295:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/64\">",
"      Farrand RJ. Recurrent haemophilus septicaemia and immunoglobulin deficiency. Arch Dis Child 1970; 45:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/65\">",
"      Miravitlles M, Espinosa C, Fern&aacute;ndez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/66\">",
"      Murphy TF. Haemophilus influenzae in chronic bronchitis. Semin Respir Infect 2000; 15:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/67\">",
"      Rello J, Rodriguez R, Jubert P, Alvarez B. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996; 23:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/68\">",
"      Brown VM, Madden S, Kelly L, et al. Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008. Clin Infect Dis 2009; 49:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/69\">",
"      Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/70\">",
"      Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/71\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/72\">",
"      Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis 2010; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/73\">",
"      Ohno A, Ishii Y, Kobayashi I, Yamaguchi K. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia. J Infect Chemother 2007; 13:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41608/abstract/74\">",
"      Resman F, Ristovski M, Forsgren A, et al. Increase of &beta;-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother 2012; 56:4408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8048 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41608=[""].join("\n");
var outline_f40_40_41608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1053902167\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Capsule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Outer membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IgA proteases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intracellular survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      H. influenzae serotype b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nontypeable H. influenzae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053902952\">",
"      BLNAR and beta-lactam-resistant H. influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053902167\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/63/20478\" title=\"table 1\">",
"      Pathogen-directed therapy for CAP in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=related_link\">",
"      Epiglottitis (supraglottitis): Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41609="Prevention of preeclampsia";
var content_f40_40_41609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of preeclampsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41609/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/40/41609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia refers to a syndrome of new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"mobipreview.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ). The syndrome is called superimposed preeclampsia when accelerating hypertension and proteinuria develop after 20 weeks in a woman with preexisting hypertension.",
"   </p>",
"   <p>",
"    The pathogenesis of preeclampsia is incompletely understood, but the disorder is clearly initiated by the presence of trophoblast. Impaired remodeling of uterine spiral arteries, reduced placental perfusion, increased inflammation, increased production of anti-angiogenic factors, and maternal endothelial cell damage are hallmarks of the disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several preexisting maternal characteristics increase the risk of preeclampsia, including hypertension, reduced renal function, obesity, insulin resistance, and diabetes. Maternal genetic or acquired thrombophilias may also be risk factors for early, severe preeclampsia, although this literature is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preeclampsia is a common cause of maternal and perinatal morbidity and mortality in both developed and developing countries. Early delivery is the only effective treatment, but necessitates preterm birth in many cases. Thus, an intervention that could prevent preeclampsia would have a significant impact on maternal and infant health worldwide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many different strategies to prevent preeclampsia have been investigated in randomized controlled trials, but none have been found to be widely effective. It is not surprising that these simple approaches have been unsuccessful, given the complexities in pathogenesis and the likelihood that multiple etiologies cause the syndrome even though the clinical manifestations of elevated blood pressure and proteinuria are common to most cases.",
"   </p>",
"   <p>",
"    Meticulous antepartum care, including close follow-up of high risk women after mid-gestation, will increase the chance that early signs of preeclampsia will not be overlooked. Thus, although preeclampsia may not be preventable at present, early diagnosis followed by appropriate management may prevent some of the dangerous sequelae of the disease, such as eclamptic seizures and multiorgan failure.",
"   </p>",
"   <p>",
"    This topic will review several interventions that have been evaluated for prevention of preeclampsia. There is no effective intervention for the general obstetrical population; low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has a small effect in women at high risk of developing preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that preeclampsia is associated with increased platelet turnover and increased platelet-derived thromboxane levels led to randomized trials evaluating low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in women thought to be at increased risk of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. As opposed to higher dose aspirin therapy, low-dose aspirin (60 to 150 mg per day) diminishes platelet thromboxane synthesis while maintaining vascular wall prostacyclin synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The drug has been studied for both prevention of preeclampsia and prevention of progression of mild to severe preeclampsia. It appears to result in a modest reduction in risk of preeclampsia when given to women at moderate to high risk of the disease.",
"   </p>",
"   <p>",
"    This approach has been studied in over 35,000 women, for both prevention of preeclampsia and prevention of progression of mild to severe preeclampsia. Low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has a modest impact on pregnancy outcome; it reduces the risk of preeclampsia, as well as other adverse pregnancy outcomes (eg, preterm delivery, fetal growth restriction) by about 10 to 15 percent. Low dose aspirin is safe in pregnancy; thus, it is a reasonable strategy in women with a moderate to high risk of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention of development of preeclampsia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Initial studies of highest risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies assessing the efficacy of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy were performed in women at especially high risk for developing preeclampsia. Entry into these studies required risk factors such as a positive angiotensin II infusion test early in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/3\">",
"     3",
"    </a>",
"    ], history of severe early-onset preeclampsia with fetal growth restriction or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/1,4\">",
"     1,4",
"    </a>",
"    ], or historical risk factors plus a positive roll over test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11480?source=see_link\">",
"     \"Prediction of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These small studies (33 to 102 patients) suggested that low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was an effective therapy in this subgroup of women; the incidence of preeclampsia was only 0 to 3 percent in treated patients versus 12 to 35 percent in controls receiving no treatment or a placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Additionally, low-dose aspirin therapy generally led to an absolute decrease in thromboxane production, relatively little change in prostacyclin or prostaglandin E synthesis, and therefore a decrease in the ratio of thromboxane to prostacyclin. By comparison, placebo therapy was associated with a progressive increase in the thromboxane to prostacyclin ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some treated women, however, had an equivalent reduction in thromboxane and prostacyclin levels with no improvement in the ratio; these women had a high rate of pregnancy-induced hypertension and did not appear to benefit from low-dose aspirin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Results from large trials of at risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above findings from initial small studies in selected women at very high risk, subsequent large trials including both moderate and high risk women did not show a significant reduction in the incidence of preeclampsia with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy. The following examples illustrate the range of findings in the largest of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Italian trial randomly assigned over 1100 patients to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (50 mg) or no therapy at 16 to 32 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/10\">",
"       10",
"      </a>",
"      ]. Criteria for inclusion included age under 18 or over 40 years, mild or moderate chronic hypertension, or history of pregnancy-induced hypertension. There were no significant differences between treatment and control groups in the incidence of pregnancy-induced",
"      <span class=\"nowrap\">",
"       hypertension/preeclampsia",
"      </span>",
"      (15 versus 19 percent in controls) or fetal complications.",
"     </li>",
"     <li>",
"      The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units double-blind study randomly assigned 2539 women to low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (60 mg) or placebo at 13 to 26 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/11\">",
"       11",
"      </a>",
"      ]. Criteria for inclusion included the presence of one of the following high-risk conditions: pregestational insulin-treated diabetes mellitus, chronic hypertension, multifetal gestation, or a previous history of preeclampsia.",
"      <br/>",
"      <br/>",
"      There was",
"      <strong>",
"       NO",
"      </strong>",
"      significant reduction in the incidence of preeclampsia with active therapy (18 versus 20 percent in controls) overall or in any of the high-risk subgroups. In the aspirin and control groups, the incidence of preeclampsia was 18 and 22 percent, respectively, among women with pregestational diabetes; 26 and 25 percent, respectively, in women with chronic hypertension; 12 and 16 percent, respectively, in multifetal gestations; and 17 and 19 percent, respectively, in women with preeclampsia in a previous pregnancy.",
"     </li>",
"     <li>",
"      The Collaborative Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      Study in Pregnancy (CLASP) trial included 9364 women at 12 to 32 weeks of gestation at increased risk of developing preeclampsia or fetal growth restriction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/12\">",
"       12",
"      </a>",
"      ]. Inclusion criteria included a previous history of preeclampsia or growth restriction, hypertension, renal disease, or other factors. There was no significant benefit of low-dose aspirin (60 mg) therapy: the incidence of proteinuric preeclampsia was 6.7 percent in the treated group versus 7.6 percent in the placebo group. However, treated patients had significantly fewer preterm deliveries, which appeared to be related to a shift in preeclampsia to later gestational ages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not statistically significant, a small decrease in the incidence of preeclampsia with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was demonstrated in each of the above trials (15 versus 19 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/10\">",
"     10",
"    </a>",
"    ], 18 versus 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/11\">",
"     11",
"    </a>",
"    ], and 6.7 versus 7.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/12\">",
"     12",
"    </a>",
"    ], respectively). When data from these and other trials were pooled, meta-analysis supported the significance of the trend observed in individual trials. Use of low dose aspirin, when started early in gestation, reduces the incidence of preeclampsia, with the greatest benefit in women at increased risk of developing the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 14 trials including over 12,000 women with historical risk factors for preeclampsia (eg, previous history of preeclampsia, chronic hypertension, diabetes, renal disease) found that low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      prophylaxis was modestly effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/13\">",
"       13",
"      </a>",
"      ]. Low-dose aspirin reduced the risk of developing preeclampsia (odds ratio [OR] 0.86, 95% CI 0.76-0.96), perinatal death (OR 0.79, 95% CI 0.64-0.96) and preterm birth (OR 0.86, 95% CI 0.79-0.94), but did not significantly affect birth weight or the risk of abruption.",
"     </li>",
"     <li>",
"      The Cochrane group assessed the safety and effectiveness of antiplatelet drugs (low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) for prevention of preeclampsia; 51 trials with over 36,000 women of varying risk status provided data for the meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/14\">",
"       14",
"      </a>",
"      ]. Use of these drugs was associated with modest, but significant, reductions in the risk of preeclampsia (RR 0.81, 95% CI 0.75-0.88), preterm birth (RR 0.93, 95% CI 0.89-0.98), and perinatal death (RR 0.84, 95% CI 0.74-0.96); a trend toward fewer small for gestational age infants (RR 0.92, 95% CI 0.85-1.00); but no difference in the incidence of abruptio placentae. The reductions were similar regardless of risk status at trial entry, whether a placebo control was used, and irrespective of the dose of low-dose aspirin or gestation at randomization.",
"     </li>",
"     <li>",
"      A meta-analysis of individual patient data from over 32,000 women of varying risk status and their babies included 31 randomized trials of primary prevention of preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/15\">",
"       15",
"      </a>",
"      ]. There were small, but statistically significant, benefits of antiplatelet agents (low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ); compared to controls, women assigned to receive antiplatelet agents had a lower risk of developing preeclampsia (RR 0.90, 95% CI 0.84&ndash;0.97), of delivering before 34 weeks (RR 0.90, 95% CI 0.83&ndash;0.98), and of having a pregnancy with a serious adverse outcome (RR 0.90, 95% CI 0.85&ndash;0.96). Antiplatelet agents had no significant effect on the risk of fetal or neonatal death, delivery of a small for gestational age infant, or bleeding events in either the women or their babies. No particular subgroup of women was substantially more or less likely to benefit from antiplatelet agents than any other.",
"     </li>",
"     <li>",
"      A meta-analysis of 34 randomized trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      versus",
"      <span class=\"nowrap\">",
"       placebo/no",
"      </span>",
"      treatment for prevention of preeclampsia found that low dose aspirin begun at &le;16 weeks of gestation was associated with a significant reduction in preeclampsia (RR 0.47, 95% CI 0.34-0.65; 9.3 versus 21.3 percent) and severe preeclampsia (RR 0.09, 95% CI 0.02-0.37; 0.7 versus 15 percent) in women at moderate to high risk of preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/16\">",
"       16",
"      </a>",
"      ]. There was no proven benefit when started after 16 weeks (RR 0.81, 95% CI 0.63-1.03; 7.3 versus 8.1 percent), but there was more heterogeneity in these trials. There was also evidence of publication bias, which may account for the large risk reduction observed in this analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Unselected nulliparous women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above studies included women with various moderate or high risk factors for preeclampsia and suggested a benefit from low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy. In contrast, two major trials limited to unselected nulliparous women, the group comprising the largest proportion of preeclampsia cases, found little or no benefit from prophylactic low-dose aspirin therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units multicenter trial randomly assigned 3000 healthy nulliparous women to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (60 mg) or placebo therapy at 13 to 26 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/17\">",
"       17",
"      </a>",
"      ]. Low-dose aspirin appeared to reduce the incidence of preeclampsia slightly (4.6 versus 6.3 percent, RR 0.7, 95% CI 0.6 to 1). The greatest effect was among the 519 patients with higher initial systolic pressures (over 120 mmHg) in whom the incidence of preeclampsia was 6 percent as compared to 12 percent in the placebo group. There were no differences between groups in birth weight or incidence of growth restriction.",
"      <br/>",
"      <br/>",
"      This trial also noted a higher incidence of abruptio placentae in the low-dose aspirin group compared to placebo (0.7 versus 0.1 percent), a finding that was not observed in all prior and subsequent studies involving over 7000 treated patients. The higher rate of abruption in this report was likely a spurious finding resulting from an unusually low rate of abruption in the placebo group (the incidence of abruption among unselected pregnant women is 0.4 to 1.3 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A multicenter French trial randomly assigned 3294 nulliparous women to receive either 100 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or placebo from inclusion at 14 to 20 weeks of gestation until 34 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/18\">",
"       18",
"      </a>",
"      ]. Women with chronic hypertension were excluded. The incidence of preeclampsia (defined as blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/90",
"      </span>",
"      mmHg and proteinuria of at least 2+ or 0.5",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      was very low and similar in both groups: 1.6 and 1.7 percent. There was no significant difference in the incidence of placental abruption or fetal growth restriction. Minor maternal bleeding was more common in the low-dose aspirin group (11.6 versus 9.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in nulliparous patients may modestly decrease the risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/17\">",
"     17",
"    </a>",
"    ], but does not affect birth weight, the incidence of fetal growth restriction, or length of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. One hypothesis for the lack of a significant effect may be that even though the incidence of preeclampsia in unselected nulliparous women is higher than in multiparas (incidence 2 to 6 versus 1 percent), it is still relatively low compared to women with risk factors such as chronic hypertension (incidence 10 percent) or renal disease (incidence 20 percent). It is also possible that the pathogenesis of preeclampsia in nulliparous women is different from that in women with previous preeclampsia or preexisting vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Women with abnormal uterine artery Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine artery Doppler velocimetry may be the best clinically available tool for identifying women at high risk of developing preeclampsia; however, the clinical value of routine Doppler surveillance has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11480?source=see_link&amp;anchor=H7#H7\">",
"     \"Prediction of preeclampsia\", section on 'Uterine artery Doppler velocimetry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A French trial randomly assigned 1253 nulliparous women to uterine artery Doppler surveillance at 23 to 24 weeks of gestation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    if the Doppler was abnormal and 617 women to no Doppler studies and placebo treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/20\">",
"     20",
"    </a>",
"    ]. Abnormal uterine artery Doppler studies were identified in 239 women. The major findings from this trial were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal uterine artery Doppler studies identified women who were likely to develop preeclampsia and fetal growth restriction (preeclampsia 6 versus 1 percent in abnormal and normal Doppler groups, respectively; growth restriction 18 versus 8 percent).",
"     </li>",
"     <li>",
"      Doppler surveillance with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treatment of the 20 percent of women with abnormal results did",
"      <strong>",
"       NOT",
"      </strong>",
"      reduce the incidence of preeclampsia compared to no surveillance. Preeclampsia occurred in approximately 2 percent of patients in each group. Treatment also did not reduce the incidence of fetal growth restriction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial confirmed the predictive value of uterine artery Doppler, but failed to demonstrate the value of routine screening followed by low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for a positive test compared to routine prenatal care. Possible limitations of this trial are that low-dose aspirin therapy was started relatively late in pregnancy (22 to 25 weeks), after significant pathologic changes had already occurred in the uteroplacental vasculature, and the low rate of preeclampsia may have precluded finding a significant reduction in disease. In a 2012 meta-analysis of trials that included only women with abnormal uterine artery Doppler flow velocimetry who started low dose aspirin at or before 16 weeks of gestation (3 trials, 346 women), aspirin reduced the risk of preeclampsia (RR 0.6, 95% CI 0.4&ndash;0.8) and severe preeclampsia (RR 0.3, 95% CI 0.1&ndash;0.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major questions remain as to whether any subgroup of women is likely to benefit from low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, when treatment should be started (first or second trimester), and the optimum dose to inhibit placental PGH synthase (cyclooxygenase) and also allow the antiinflammatory effects of low-dose aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/22\">",
"     22",
"    </a>",
"    ]. The following summaries represent the conclusions of some major groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Obstetricians and Gynecologists practice bulletin does not recommend low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy for women at low-risk for development of preeclampsia (",
"      <a class=\"graphic graphic_table graphicRef61266 \" href=\"mobipreview.htm?43/39/44667\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/23\">",
"       23",
"      </a>",
"      ]. However, no conclusions were reached about moderate to high risk women.",
"     </li>",
"     <li>",
"      A Cochrane review concluded that for moderate and high risk women, 59 to 167 patients would have to be treated to prevent one case of preeclampsia; 44 to 200 would have to be treated to prevent one preterm birth; and 125 to over 10,000 would have to be treated to prevent one perinatal death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The NICE guideline on management of hypertensive disorders during pregnancy advises use of low dose (75 mg)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for women with at least one high risk factor for preeclampsia (chronic hypertension or kidney disease, diabetes, autoimmune disease, hypertension in previous pregnancy) or at least two moderate risk factors for preeclampsia (age &ge;40 years, first pregnancy, multiple gestation, &gt;10 years between pregnancies, body mass index &ge;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      at presentation, family history of preeclampsia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Chest Physicians guidelines for management of venous thromboembolism, thrombophilia, and pregnancy recommend low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      starting from the second trimester and continuing throughout pregnancy in women considered to be at risk for preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/26\">",
"       26",
"      </a>",
"      ]. They support the recommendations of a Cochrane review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/24\">",
"       24",
"      </a>",
"      ], which emphasizes that the greater the baseline risk, the smaller the number needed to treat to prevent preeclampsia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the available data, some maternal-fetal medicine specialists recommend low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for women at moderate or high risk for preeclampsia, as there is a potential for benefit with minimal risk. There is no consensus on the criteria that confer significant risk; previous pregnancy with early preeclampsia and a poor fetal outcome, type 1 diabetes mellitus with vascular involvement, antiphospholipid syndrome, and poorly controlled chronic hypertension are the most common indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If used, treatment should be begun at 12 to 14 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/16,25,28\">",
"     16,25,28",
"    </a>",
"    ]. The optimum low dose is unclear; 81 mg is readily available. The safety of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use in the second and third trimesters is well-established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/6,13,29\">",
"     6,13,29",
"    </a>",
"    ], but questions linger regarding use in the first trimester. Early therapy is probably important since the pathophysiologic features of preeclampsia develop at this time, weeks before clinical disease is apparent. Aspirin is discontinued 5 to 10 days before expected delivery to diminish the risk of bleeding during delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/2,5,30\">",
"     2,5,30",
"    </a>",
"    ]; however, no adverse maternal or fetal effects related to low-dose aspirin have been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of worsening preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appears to be of little or no benefit in women who already have developed pregnancy-induced hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/6,12,31\">",
"     6,12,31",
"    </a>",
"    ]. At this late stage, aspirin does not prevent progression to more severe disease and may exacerbate a bleeding diathesis in patients with the HELLP syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preeclamptic placenta displays characteristic features of uteroplacental ischemia, including increased syncytial knots and intervillous fibrin, distal villous hypoplasia, villous infarcts, decidual necrosis, and spiral artery abnormalities including acute atherosis, mural hypertrophy, and luminal",
"    <span class=\"nowrap\">",
"     thrombosis/fibrous",
"    </span>",
"    obliteration. Prophylactic anticoagulation in selected high risk women, particularly those with previous early severe preeclampsia, has been suggested to minimize formation of thrombi and maintain perfusion, although thrombus formation is a minor component of these uteroplacental abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. This area remains controversial.",
"   </p>",
"   <p>",
"    No large randomized trials have evaluated the use of anticoagulation (unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin) for prevention of preeclampsia in women with or without thrombophilias or in women with previous severe or preterm preeclampsia, although several such trials are currently in progress. Some small studies of heparin or low molecular weight heparin with or without an antiplatelet agent have suggested a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/36-40\">",
"     36-40",
"    </a>",
"    ], but a systematic review did not find this therapy useful in prevention of adverse late pregnancy placenta-mediated outcomes (eg, perinatal death, preterm birth &lt;34 weeks, neurodevelopmental delay) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/41\">",
"     41",
"    </a>",
"    ]; most of the studies were in highly selected populations.",
"   </p>",
"   <p>",
"    Further investigation is required; anticoagulation is not recommended for reducing the risk of preeclampsia in either the general population or in those with preeclampsia in a previous pregnancy. Whether anticoagulation is effective in preventing preeclampsia in women with previous early preeclampsia remains an unresolved question that warrants further study.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=see_link\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CALCIUM SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , there does not appear to be any benefit to routine calcium supplementation for healthy, nulliparous women in whom baseline dietary calcium intake is adequate. There may be a benefit for preeclampsia prevention in some high-risk populations, particularly those who eat a low calcium diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium supplementation (1.5 to 2 g of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    per day in divided doses) has been evaluated for prevention of hypertensive disorders of pregnancy. The potential value of this approach was illustrated in a systematic review of 13 randomized trials including over 15,000 women that assessed the effects of calcium supplementation on development of pregnancy-related hypertensive disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/42\">",
"     42",
"    </a>",
"    ]. Calcium supplementation appeared to approximately halve the risk of preeclampsia (RR 0.45, 95% CI 0.31-0.65), to reduce the risk of preterm birth (RR 0.76, 95% CI 0.60-0.97), and to reduce the rare occurrence of the composite outcome &ldquo;maternal death or serious morbidity&rdquo; (RR 0.80, 95% CI 0.65-0.97). There were no other clear benefits, or harms. The reduction in risk ratio was greatest for women at high risk of preeclampsia (five trials, 587 women: RR 0.22, 95% CI 0.12-0.42), and for those with low baseline calcium intake (eight trials, 10,678 women: RR 0.36, 95% CI 0.20-0.65). The largest trial of women with low baseline calcium intake did not show a substantial reduction in preeclampsia, but there was a significant reduction in early",
"    <span class=\"nowrap\">",
"     onset/severe",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of the characteristics of the population being supplemented was demonstrated in the Calcium for Preeclampsia Prevention (CPEP) performed in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/44\">",
"     44",
"    </a>",
"    ]. In this trial, 4589 healthy nulliparous women at 13 to 21 weeks of gestation were randomly assigned to receive either calcium (2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo therapy for the rest of their pregnancy. No benefit of calcium supplementation was identified: there were no differences between the two groups in the incidence of preeclampsia (6.9 versus 7.3 percent), pregnancy-associated hypertension, or adverse fetal outcomes.",
"   </p>",
"   <p>",
"    The negative results of this large trial of relatively low risk women are compatible with results of meta-analyses where studies were stratified by the presence of a placebo-controlled group, by high-risk and low-risk populations, and by baseline dietary calcium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/42,45-47\">",
"     42,45-47",
"    </a>",
"    ]. Meta-analyses of placebo-controlled trials in low-risk women with adequate dietary calcium intake generally showed that calcium supplementation has no significant benefit in preventing preeclampsia in contrast to studies in high risk, low calcium intake populations . Although the most recent metaanalysis concluded that calcium supplementation was effective in reducing the risk of preeclampsia, even in low risk women, two-thirds of these women had low dietary calcium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of additional interest, in some studies, maternal calcium supplementation in the second trimester appeared to result in a small, but statistically significant, lowering of blood pressure in offspring when measured up to age 9 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, others have not found a clinically significant effect on offspring blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIOXIDANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of preeclampsia has been described as a two-stage process: reduced placental perfusion followed by the release of placental factors that trigger maternal endothelial cell dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/51\">",
"     51",
"    </a>",
"    ]. Oxidative stress may be a cause of this endothelial cell dysfunction. This hypothesis is supported by the observation that markers of oxidative stress are present in the maternal circulation of affected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/52\">",
"     52",
"    </a>",
"    ]. For this reason, antioxidants have been proposed for prevention and treatment of preeclampsia. Antioxidants also have other effects that may or may not be detrimental to pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review of seven trials involving over 6000 women assessed the effectiveness of any antioxidant supplement during pregnancy for prevention of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/54\">",
"     54",
"    </a>",
"    ]. Supplements included various doses and combinations of vitamin C, vitamin E,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , halibut liver oil (containing vitamin A), fish oil, and lycopene, sometimes with other interventions (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ). Supplementation with any antioxidants during pregnancy compared with no treatment or a placebo was associated with a 39 percent reduction in the relative risk of preeclampsia (RR 0.61, 95% CI 0.50-0.75), which corresponds to an absolute risk reduction of 3 percent. There was also a reduction in birth of small for gestational age infants (RR 0.64, 95% CI 0.47-0.87), but a slight increase in preterm birth (RR 1.38, 95% CI 1.04-1.82). The clinical utility of these results is limited because most of the data came from poor quality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    quasi-randomized studies. There were insufficient data for reliable conclusions about the possible impact of this therapy in subgroups of high or low risk women, or to provide guidance on the optimal type and dosage of antioxidant(s) or timing of supplementation.",
"   </p>",
"   <p>",
"    Subsequent data from large well-designed randomized trials continue to show a lack of benefit and are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitamins C and E",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend antioxidant supplementation with vitamin C",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    E for prevention or treatment of preeclampsia. There is high quality evidence that it is not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38921492\">",
"    <span class=\"h3\">",
"     For prevention of preeclampsia and its complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a pilot trial reported vitamin C (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and vitamin E (400",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    supplementation during the second and third trimesters significantly reduced the risk of developing preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/55\">",
"     55",
"    </a>",
"    ], multiple subsequent large, randomized, multicenter trials including women at both high and low risk of developing preeclampsia have consistently refuted these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/56-63\">",
"     56-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of nine such trials involving a total of almost 20,000 women confirmed this finding and also found that supplementation was associated with a slightly increased risk of gestational hypertension (RR 1.11, 95% CI 1.05-1.17), but this could have been the result of multiple statistical comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Similarly, two trials included in a meta-analysis noted that supplementation was associated with an increased risk of premature rupture of membranes (RR 1.73, 95% CI 1.34-2.23) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/65\">",
"     65",
"    </a>",
"    ], but not preterm premature rupture of membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38921500\">",
"    <span class=\"h3\">",
"     For treatment of preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two studies, antioxidants were given to women who already had severe preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Neither reported a clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that fish oil supplements may have a variety of protective vascular effects, including reductions in systemic blood pressure and in the incidence of preeclampsia and pregnancy-induced hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, the bulk of evidence does not support the use of fish oil for prevention of preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective trial enrolled 386 pregnant women with a history of pregnancy-induced hypertension in a previous pregnancy and randomly assigned them to a fish oil or olive oil supplement, beginning after 16 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/70\">",
"     70",
"    </a>",
"    ]. A second, therapeutic trial enrolled 79 pregnant women who were beginning to develop preeclampsia and randomly assigned them to the same two formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/71\">",
"     71",
"    </a>",
"    ]. These, and two subsequent trials, found that fish oil supplementation had no effect on the incidence or development of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Meta-analysis of these trials also failed to show a reduction in risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER DIETARY INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few small randomized trials evaluating the role of diet in prevention of preeclampsia. No beneficial results have been demonstrated from these interventions, which include nutritional advice, protein and energy supplements, protein and energy restriction (in obese women), magnesium supplementation, and salt restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/73,75,76\">",
"     73,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359380\">",
"    <span class=\"h2\">",
"     Vitamin D supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some observational studies have reported an association between vitamin D deficiency and an increased risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/77\">",
"     77",
"    </a>",
"    ] and early onset severe preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/78\">",
"     78",
"    </a>",
"    ], but a prospective cohort study of women at high risk for preeclampsia did not find an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, one study using data from questionnaires observed a 29 percent reduction in risk of preeclampsia among women who reported consumption of vitamin D supplements (10 to 15",
"    <span class=\"nowrap\">",
"     microg/day",
"    </span>",
"    [400 to 600",
"    <span class=\"nowrap\">",
"     IU/day])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/80\">",
"     80",
"    </a>",
"    ]. An association has also been observed between a diet characterized by high intake of vegetables, fruits, and vegetable oils and a reduced risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/81\">",
"     81",
"    </a>",
"    ]. Clinical trials evaluating these approaches have not been performed.",
"   </p>",
"   <p>",
"    It is not necessary to check vitamin D levels in reproductive aged women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Candidates for 25OHD measurements'",
"    </a>",
"    .) Pregnant women who do not have regular effective sun exposure should consume 600 IU of vitamin D daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link&amp;anchor=H19#H19\">",
"     \"Nutrition in pregnancy\", section on 'Multivitamin and mineral supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359387\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although maternal obesity is associated with an increased risk of preeclampsia, few studies have evaluated the effect of weight loss on this risk. Cohort studies of women who underwent bariatric surgery suggest that weight loss significantly reduces the risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, a cohort study of women with preeclampsia found weight loss between pregnancies reduced the risk of recurrent preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTIHYPERTENSIVE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled studies have",
"    <strong>",
"     NOT",
"    </strong>",
"    demonstrated that lowering the blood pressure with antihypertensive medications (including diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/84\">",
"     84",
"    </a>",
"    ]) reduces the risk of preeclampsia or abruption, or improves fetal or maternal outcome; however, therapy does decrease the incidence of severe hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NITRIC OXIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclamptic women may be deficient in nitric oxide, which mediates vasodilatation and inhibits platelet aggregation. However, there is no high quality evidence that administration of nitric oxide donors (glyceryl trinitrate) prevents preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    L-arginine, the substrate for synthesis of nitric oxide, has been investigated as a means of preventing preeclampsia. In a small randomized trial that tested this approach in women with a history of preeclampsia in a previous pregnancy (a group who would be expected to have a recurrence rate of between 5 to 20 percent), supplementation with medical food-bars containing L-arginine plus antioxidant vitamin was associated with a significant reduction in the incidence of preeclampsia compared with placebo (29 percent",
"    <span class=\"nowrap\">",
"     [13/228]",
"    </span>",
"    versus 67 percent",
"    <span class=\"nowrap\">",
"     [30/222];",
"    </span>",
"    RR 0.17, 95% CI 0.12-0.21) and compared with use of antioxidant vitamins alone (29 percent",
"    <span class=\"nowrap\">",
"     [13/228]",
"    </span>",
"    versus 50 percent",
"    <span class=\"nowrap\">",
"     [23/222];",
"    </span>",
"    RR 0.09, 95% CI 0.05-0.14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/86\">",
"     86",
"    </a>",
"    ]. The mean gestational age at delivery was &gt;38 weeks, regardless of treatment assignment, and there were no differences between groups in mean infant birthweight, proportion of small for gestational age infants, or rate of abruption. Thus, it appears that most of these women had mild preeclampsia, and the experimental treatment did not have an important impact on meaningful clinical outcomes.&nbsp;The clinical significance of these findings remains unclear, and whether this strategy would have any benefit in preventing morbidity associated with preeclampsia remains unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16526630\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence that exercise and physical activity affect the risk of developing preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41609/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is the only drug for which there is some evidence of benefit in reducing the risk of preeclampsia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antiplatelet agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women at low-risk for development of preeclampsia, we recommend avoiding low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). There is no evidence of benefit.",
"     </li>",
"     <li>",
"      For women at moderate to high risk of developing preeclampsia, we suggest low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A modest reduction in the risk of preeclampsia is possible. No therapy is a reasonable alternative, given that we cannot easily identify a group of pregnant women who will predictably derive a clinically significant benefit from low-dose aspirin therapy. There is no consensus on criteria to define women at moderate to high risk for preeclampsia.",
"      <br/>",
"      <br/>",
"      The optimum low dose of aspirin is unclear; we suggest 81 mg per day (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), beginning at the end of the first trimester. Aspirin is discontinued 5 to 10 days before expected delivery to diminish the risk of bleeding during delivery; however, no adverse maternal or fetal effects related to low-dose aspirin have been proven. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We do not recommend routine calcium supplementation for healthy, nulliparous women to prevent preeclampsia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). There may be a benefit for preeclampsia prevention in high-risk populations or in those consuming a low calcium diet. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Calcium supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend vitamin C and E supplementation to prevent preeclampsia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamins C and E'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend fish oil for preventing preeclampsia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fish oil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No drug prevents progression to more severe disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of worsening preeclampsia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamins C and E'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/1\">",
"      Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/2\">",
"      Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/3\">",
"      Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/4\">",
"      Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/5\">",
"      McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990; 335:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/6\">",
"      Dekker GA, Sibai BM. Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. Am J Obstet Gynecol 1993; 168:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/7\">",
"      Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/8\">",
"      Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/9\">",
"      Brown CE, Gant NF, Cox K, et al. Low-dose aspirin. II. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome. Am J Obstet Gynecol 1990; 163:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/10\">",
"      Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet 1993; 341:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/11\">",
"      Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/12\">",
"      CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/13\">",
"      Coomarasamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/14\">",
"      Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004; :CD004659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/15\">",
"      Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/16\">",
"      Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/17\">",
"      Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/18\">",
"      Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai R&eacute;gional Aspirine M&egrave;re-Enfant study (Part 1). BJOG 2003; 110:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/19\">",
"      Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/20\">",
"      Subtil D, Goeusse P, Houfflin-Debarge V, et al. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai R&eacute;gional Aspirine M&egrave;re-Enfant study (Part 2). BJOG 2003; 110:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/21\">",
"      Villa PM, Kajantie E, R&auml;ikk&ouml;nen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013; 120:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/22\">",
"      Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001; 357:209.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin #33. American College of Obstetricians and Gynecologists, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/24\">",
"      Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2000; :CD000492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/25\">",
"      Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/26\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/27\">",
"      Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008; 112:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/28\">",
"      Paller MS. Hypertension in pregnancy. J Am Soc Nephrol 1998; 9:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/29\">",
"      Kozer E, Costei AM, Boskovic R, et al. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003; 68:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/30\">",
"      Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/31\">",
"      Schiff E, Barkai G, Ben-Baruch G, Mashiach S. Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension. Obstet Gynecol 1990; 76:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/32\">",
"      Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/33\">",
"      Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/34\">",
"      Mello G, Parretti E, Marozio L, et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/35\">",
"      Facchinetti F, Marozio L, Frusca T, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200:46.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/36\">",
"      Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/37\">",
"      Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/38\">",
"      North RA, Ferrier C, Gamble G, et al. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/39\">",
"      Sergio F, Maria Clara D, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/40\">",
"      Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/41\">",
"      Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010; :CD006780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/42\">",
"      Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010; :CD001059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/43\">",
"      Villar J, Abdel-Aleem H, Merialdi M, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006; 194:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/44\">",
"      Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997; 337:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/45\">",
"      DerSimonian R, Levine RJ. Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. JAMA 1999; 282:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/46\">",
"      Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2002; :CD001059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/47\">",
"      Trumbo PR, Ellwood KC. Supplemental calcium and risk reduction of hypertension, pregnancy-induced hypertension, and preeclampsia: an evidence-based review by the US Food and Drug Administration. Nutr Rev 2007; 65:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/48\">",
"      Gillman MW, Rifas-Shiman SL, Kleinman KP, et al. Maternal calcium intake and offspring blood pressure. Circulation 2004; 110:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/49\">",
"      Beliz&aacute;n JM, Villar J, Bergel E, et al. Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial. BMJ 1997; 315:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/50\">",
"      Bakker R, Rifas-Shiman SL, Kleinman KP, et al. Maternal calcium intake during pregnancy and blood pressure in the offspring at age 3 years: a follow-up analysis of the Project Viva cohort. Am J Epidemiol 2008; 168:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/51\">",
"      Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 1999; 354:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/52\">",
"      Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 2004; 24:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/53\">",
"      Banerjee S, Chambers AE, Campbell S. Is vitamin E a safe prophylaxis for preeclampsia? Am J Obstet Gynecol 2006; 194:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/54\">",
"      Rumbold A, Duley L, Crowther C, Haslam R. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2005; :CD004227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/55\">",
"      Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999; 354:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/56\">",
"      Beazley D, Ahokas R, Livingston J, et al. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 2005; 192:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/57\">",
"      Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/58\">",
"      Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/59\">",
"      Spinnato JA 2nd, Freire S, Pinto E Silva JL, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 2007; 110:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/60\">",
"      Villar J, Purwar M, Merialdi M, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009; 116:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/61\">",
"      Xu H, Perez-Cuevas R, Xiong X, et al. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol 2010; 202:239.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/62\">",
"      Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/63\">",
"      McCance DR, Holmes VA, Maresh MJ, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 2010; 376:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/64\">",
"      Basaran A, Basaran M, Topatan B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv 2010; 65:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/65\">",
"      Conde-Agudelo A, Romero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204:503.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/66\">",
"      Stratta P, Canavese C, Porcu M, et al. Vitamin E supplementation in preeclampsia. Gynecol Obstet Invest 1994; 37:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/67\">",
"      G&uuml;lmezo��lu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. Br J Obstet Gynaecol 1997; 104:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/68\">",
"      Secher NJ, Olsen SF. Fish-oil and pre-eclampsia. Br J Obstet Gynaecol 1990; 97:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/69\">",
"      S&oslash;rensen JD, Olsen SF, Pedersen AK, et al. Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production. Am J Obstet Gynecol 1993; 168:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/70\">",
"      Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000; 107:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/71\">",
"      Onwude JL, Lilford RJ, Hjartardottir H, et al. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol 1995; 102:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/72\">",
"      Smuts CM, Huang M, Mundy D, et al. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet Gynecol 2003; 101:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/73\">",
"      Villar J, Abalos E, Nardin JM, et al. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 2004; 24:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/74\">",
"      Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev 2006; :CD003402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/75\">",
"      Duley L, Henderson-Smart D, Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev 2005; :CD005548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/76\">",
"      Brice&ntilde;o-P&eacute;rez C, Brice&ntilde;o-Sanabria L, Vigil-De Gracia P. Prediction and prevention of preeclampsia. Hypertens Pregnancy 2009; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/77\">",
"      Bodnar LM, Catov JM, Simhan HN, et al. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007; 92:3517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/78\">",
"      Robinson CJ, Alanis MC, Wagner CL, et al. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. Am J Obstet Gynecol 2010; 203:366.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/79\">",
"      Shand AW, Nassar N, Von Dadelszen P, et al. Maternal vitamin D status in pregnancy and adverse pregnancy outcomes in a group at high risk for pre-eclampsia. BJOG 2010; 117:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/80\">",
"      Haugen M, Brantsaeter AL, Trogstad L, et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology 2009; 20:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/81\">",
"      Brantsaeter AL, Haugen M, Samuelsen SO, et al. A dietary pattern characterized by high intake of vegetables, fruits, and vegetable oils is associated with reduced risk of preeclampsia in nulliparous pregnant Norwegian women. J Nutr 2009; 139:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/82\">",
"      Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/83\">",
"      Mostello D, Jen Chang J, Allen J, et al. Recurrent preeclampsia: the effect of weight change between pregnancies. Obstet Gynecol 2010; 116:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/84\">",
"      Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev 2007; :CD004451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/85\">",
"      Meher S, Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; :CD006490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/86\">",
"      Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011; 342:d2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41609/abstract/87\">",
"      Kasawara KT, do Nascimento SL, Costa ML, et al. Exercise and physical activity in the prevention of pre-eclampsia: systematic review. Acta Obstet Gynecol Scand 2012; 91:1147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6817 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41609=[""].join("\n");
var outline_f40_40_41609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention of development of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Initial studies of highest risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Results from large trials of at risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Unselected nulliparous women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Women with abnormal uterine artery Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of worsening preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CALCIUM SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIOXIDANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitamins C and E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38921492\">",
"      - For prevention of preeclampsia and its complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38921500\">",
"      - For treatment of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER DIETARY INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359380\">",
"      Vitamin D supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359387\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTIHYPERTENSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NITRIC OXIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16526630\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/39/44667\" title=\"table 2\">",
"      Risk factors for preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11480?source=related_link\">",
"      Prediction of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41610="Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer";
var content_f40_40_41610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Carlos Fernandez-del Castillo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/40/41610/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/40/41610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the exocrine pancreas is a highly lethal malignancy. It is the fourth leading cause of cancer-related death in the United States and second only to colorectal cancer as a cause of digestive cancer-related death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Epidemiology'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Surgical resection is the only potentially curative treatment. Unfortunately, because of the late presentation, only 15 to 20 percent of patients are candidates for pancreatectomy. Furthermore, prognosis is poor, even after a complete resection. Five-year survival after pancreaticoduodenectomy is about 25 to 30 percent for node-negative and 10 percent for node-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation, diagnostic evaluation, and staging workup for pancreatic exocrine cancer will be reviewed here. Epidemiology and risk factors, pathology, surgical management, adjuvant and neoadjuvant therapy, and treatment of advanced pancreatic exocrine cancer, including palliative local management, are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"       \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link\">",
"       \"Pathology of exocrine pancreatic neoplasms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"       \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link\">",
"       \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158746930\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commonly used term \"pancreatic cancer\" usually refers to a ductal adenocarcinoma of the pancreas (including its subtypes), which represents about 85 percent of all pancreatic neoplasms. Of the several subtypes of ductal adenocarcinoma, most share a similar poor long-term prognosis, with the exception of colloid carcinomas, which have a somewhat better prognosis. The more inclusive term \"exocrine pancreatic neoplasms\" includes all tumors that are related to the pancreatic ductal and acinar cells and their stem cells (including pancreatoblastoma), and is preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 95 percent of malignant neoplasms of the pancreas arise from the exocrine elements. Neoplasms arising from the endocrine pancreas (ie, pancreatic neuroendocrine [islet cell] tumors) comprise no more than 5 percent of pancreatic neoplasms; their clinical manifestations, diagnosis, and staging is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms in patients with exocrine pancreatic cancer are pain, jaundice, and weight loss. In a multi-institutional series of 185 patients with exocrine pancreatic cancer diagnosed over a three-year period (62 percent involving the head of the gland, 10 percent body, 6 percent tail, and the remainder not determined), the most frequent symptoms at diagnosis were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthenia &ndash; 86 percent",
"     </li>",
"     <li>",
"      Weight loss &ndash; 85 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 83 percent",
"     </li>",
"     <li>",
"      Abdominal pain &ndash; 79 percent",
"     </li>",
"     <li>",
"      Epigastric pain &ndash; 71 percent",
"     </li>",
"     <li>",
"      Dark urine &ndash; 59 percent",
"     </li>",
"     <li>",
"      Jaundice &ndash; 56 percent",
"     </li>",
"     <li>",
"      Nausea &ndash; 51 percent",
"     </li>",
"     <li>",
"      Back pain &ndash; 49 percent",
"     </li>",
"     <li>",
"      Diarrhea- 44 percent",
"     </li>",
"     <li>",
"      Vomiting &ndash; 33 percent",
"     </li>",
"     <li>",
"      Steatorrhea &ndash; 25 percent",
"     </li>",
"     <li>",
"      Thrombophlebitis &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most frequent signs were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jaundice &ndash; 55 percent",
"     </li>",
"     <li>",
"      Hepatomegaly- 39 percent",
"     </li>",
"     <li>",
"      Right upper quadrant mass &ndash; 15 percent",
"     </li>",
"     <li>",
"      Cachexia &ndash; 13 percent",
"     </li>",
"     <li>",
"      Courvoisier&rsquo;s sign (nontender but palpable distended gallbladder at the right costal margin) &ndash; 13 percent",
"     </li>",
"     <li>",
"      Epigastric mass &ndash; 9 percent",
"     </li>",
"     <li>",
"      Ascites &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial presentation of pancreatic cancer varies according to tumor location. Approximately 60 to 70 percent of exocrine pancreatic cancers are localized to the head of the pancreas, while 20 to 25 percent are in the",
"    <span class=\"nowrap\">",
"     body/tail",
"    </span>",
"    and the remainder involve the whole organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/2\">",
"     2",
"    </a>",
"    ]. Compared to tumors in the body and tail of the gland, pancreatic head tumors more often present with jaundice, steatorrhea, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. As an example, in the above noted series, jaundice was present in 73 percent of the 114 patients with a tumor located in the head of the pancreas, compared to 11 percent of 19 body lesions, and none of the 11 tail lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/1\">",
"     1",
"    </a>",
"    ]. Steatorrhea was present in 28 percent of the patients with pancreatic head lesions versus 11 percent of those with body, and none of those with tail lesions. Steatorrhea is attributable to loss of the pancreas&rsquo; ability to secrete fat-digesting enzymes or to blockage of the main pancreatic duct. &nbsp;",
"   </p>",
"   <p>",
"    Pain is one of the most frequently reported symptoms, even with small (&lt;2 cm) pancreatic cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The pain associated with pancreatic cancer is usually insidious in onset, and has been present for one to two months at the time of presentation. It has a typical gnawing visceral quality, and is generally epigastric, radiating to the sides",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    straight through to the back. It may be intermittent and made worse by eating or lying supine. It is frequently worse at night. Lying in a curled or fetal position may improve the pain. Severe back pain should raise suspicion for a tumor arising in the body and tail of the pancreas. Rarely, pain develops very acutely, as a result of an episode of acute pancreatitis due to tumoral occlusion of the main pancreatic duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jaundice, which is usually progressive, is most often due to obstruction of the common bile duct by a mass in the head of the pancreas, causing hyperbilirubinemia. Jaundice may be accompanied by pruritus, darkening of the urine, and pale stools. Hyperbilirubinemia is characteristically of the cholestatic type, with a predominant increase in the conjugated fraction of bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jaundice is a relatively early sign in tumors arising from the pancreatic head, and pancreatic tumors that present with painless jaundice have been ascribed a relatively more favorable prognosis compared to those that present with pain and obstructive jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Jaundice secondary to a tumor in the body or tail typically occurs later in the course of the disease, and may be secondary to liver metastases.",
"   </p>",
"   <p>",
"    A recent onset of atypical diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] may be noted. Several studies have addressed whether earlier detection of nonspecific signs of an evolving pancreatic neoplasm (particularly in adults with new-onset diabetes mellitus) might improve resectability and overall outcomes, but the results are inconclusive. Screening for pancreatic cancer in adults with new onset diabetes mellitus is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Diabetes mellitus, glucose metabolism, and insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unexplained superficial thrombophlebitis, which may be migratory (classic Trousseau&rsquo;s syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/12\">",
"     12",
"    </a>",
"    ], is sometimes present and reflects the hypercoagulable state that frequently accompanies pancreatic cancer. There is a particularly high incidence of thromboembolic (both venous and arterial) events, particularly in the setting of advanced disease, and clinicians should maintain a high index of suspicion. Thromboembolic complications occur more commonly in patients with tumors arising in the tail or body of the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin manifestations occur as paraneoplastic phenomena in some patients. As an example, both cicatricial and bullous pemphigoid are described, even as a first sign of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H21#H21\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Paraneoplastic pemphigus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, erythematous subcutaneous areas of nodular fat necrosis, typically located on the legs (pancreatic panniculitis), may be evident, particularly in patients with the acinar cell variant of pancreatic cancer (",
"    <a class=\"graphic graphic_figure graphicRef85874 \" href=\"mobipreview.htm?37/32/38407\">",
"     figure 1",
"    </a>",
"    ). It is hypothesized that the condition is initiated by autodigestion of subcutaneous fat secondary to systemic spillage of excess digestive pancreatic enzymes. The presence of this condition is not pathognomonic for an exocrine pancreatic cancer, as it has been described with pancreatic neuroendocrine tumors, intraductal papillary mucinous neoplasms, and in chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H5#H5\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Pancreatic panniculitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Acinar cell carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link\">",
"     \"Panniculitis: Recognition and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of metastatic disease may be present at presentation. Metastatic disease most commonly affects the liver, peritoneum, lungs, and less frequently, bone. Signs of advanced, incurable disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An abdominal mass or ascites",
"     </li>",
"     <li>",
"      Left supraclavicular lymphadenopathy (Virchow's node)",
"     </li>",
"     <li>",
"      A palpable periumbilical mass (Sister Mary Joseph&rsquo;s node) or a palpable rectal shelf are present in some patients with widespread disease. Pancreatic cancer is the origin of a cutaneous metastasis to the umbilicus in 7 to 9 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine laboratory tests are often abnormal, but are not specific for pancreatic cancer. Common abnormalities include an elevated serum bilirubin and alkaline phosphatase levels, and the presence of mild anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18017807\">",
"    <span class=\"h2\">",
"     Incidental finding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A solid pancreatic lesion is uncommonly found as an incidental finding on CT scans done for another reason. In one report, 24 of the 321 patients with a solid pancreatic mass who were identified over an eight-year period had it incidentally discovered (7 percent); one-half of these were adenocarcinomas, while the remainder were pancreatic neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/16\">",
"     16",
"    </a>",
"    ]. The majority of pancreatic lesions discovered on radiographic studies performed for another reason are cystic, and many of these represent intraductal papillary mucinous neoplasms, which represent a precursor lesion to exocrine pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5507120#H5507120\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H8191539#H8191539\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Progression to pancreatic cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158746981\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms associated with pancreatic cancer are often nonspecific, so the differential diagnosis is large. Three of the more common findings leading to suspicion for pancreatic cancer are jaundice, epigastric pain, and weight loss.",
"   </p>",
"   <p>",
"    The positive predictive value (PPV) of these symptoms for the diagnosis of pancreatic cancer is low, with the possible exception of jaundice in an older patient. This was shown in a case-control study that examined the risk of pancreatic cancer based upon symptoms that were identified in the year before diagnosis in 21,624 patients seen in a primary care clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/17\">",
"     17",
"    </a>",
"    ]. The PPV of jaundice for pancreatic cancer in a patient aged 60 or older was 22 percent; it was &lt;3 percent for all other single symptoms or pairs of non-jaundice symptoms, even in older individuals. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747091\">",
"    <span class=\"h2\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of the jaundiced patient is broad; a classification of jaundice according to the type of bile pigment and underlying mechanism of hyperbilirubinemia is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef55607 \" href=\"mobipreview.htm?27/55/28541\">",
"     table 1",
"    </a>",
"    ). Patients with biliary obstruction due to pancreatic cancer usually present with conjugated hyperbilirubinemia, and the differential diagnosis includes choledocholithiasis, biliary obstruction from other malignant tumors or adenomas, intrahepatic cholestasis, and acute or chronic hepatocellular injury (",
"    <a class=\"graphic graphic_algorithm graphicRef62683 \" href=\"mobipreview.htm?18/37/19038\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnostic evaluation of a jaundiced patient with biliary obstruction is designed to eliminate benign tumors or gallstones from the differential, and to establish the location and extent of tumor invasion and spread if a malignant bile duct obstruction is detected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747200\">",
"    <span class=\"h2\">",
"     Epigastric pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epigastric pain in adults is broad. Most patients with pancreatic cancer and abdominal pain have pain that has been present for more than three days, but not for many months. As such, they generally fall into the category of subacute pain, and the causes of both acute and chronic pain need to be included in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Acute versus chronic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach generally depends on the history, location of the pain, tempo, and the general suspicion for benign versus malignant disease based upon associated symptoms such as weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163256719\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the causes of involuntary weight loss include malignancies, endocrinopathies, and psychiatric diseases. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=see_link&amp;anchor=H88396429#H88396429\">",
"     \"Approach to the patient with weight loss\", section on 'Involuntary weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747219\">",
"    <span class=\"h2\">",
"     Pancreatic mass seen on an imaging study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid pancreatic masses may be detected incidentally on abdominal imaging studies. (See",
"    <a class=\"local\" href=\"#H18017807\">",
"     'Incidental finding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of a pancreatic mass depends upon whether the mass is cystic or solid. Cystic pancreatic lesions include non-neoplastic cysts (eg, true cysts, retention cysts) and pancreatic cystic neoplasms (eg, intraductal papillary mucinous neoplasm of the pancreas, serous cystic tumors, and mucinous cystic neoplasms). The classification and evaluation of cystic pancreatic lesions is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of a solid pancreatic mass seen on a radiographic imaging study includes a primary exocrine pancreatic cancer, a pancreatic neuroendocrine tumor, lymphoma (rare), metastatic cancer (rare), focal chronic pancreatitis, and autoimmune pancreatitis.",
"   </p>",
"   <p>",
"    Pancreatic neuroendocrine tumors are typically highly vascular with enhancement in the early arterial phase and washout in the early portal venous phase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rare, the diagnosis of a pancreatic metastasis may be considered in a patient who has evidence of malignant disease in other sites.",
"   </p>",
"   <p>",
"    Clues suggesting the possibility of a primary pancreatic lymphoma include a lack of jaundice, constitutional symptoms (weight loss, fever, and night sweats), an elevated serum lactate dehydrogenase (LDH) or beta-2 microglobulin level, and a normal serum CA 19&ndash;9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Primary pancreatic lymphomas are typically larger than 6 cm, and surrounding lymphadenopathy is common as with any lymphoma; however, neither of these features would exclude adenocarcinoma.",
"   </p>",
"   <p>",
"    An endoscopic ultrasound (EUS)-guided biopsy may be recommended if a diagnosis of chronic or autoimmune pancreatitis is suspected on the basis of history (eg, extreme young age, prolonged ethanol abuse, history of other autoimmune diseases), particularly if further imaging studies (either EUS, endoscopic retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography) reveal multifocal biliary strictures (suggestive of autoimmune pancreatitis) or diffuse pancreatic ductal changes (suggestive of chronic pancreatitis).",
"   </p>",
"   <p>",
"    Among patients who have a mass in the head of the pancreas or a malignant bile duct obstruction in the vicinity of the distal common bile duct, differentiating a primary exocrine pancreatic carcinoma from other less common periampullary malignancies (arising in the ampulla, duodenum, or bile duct) can be challenging (",
"    <a class=\"graphic graphic_figure graphicRef53240 \" href=\"mobipreview.htm?5/49/5908\">",
"     figure 2",
"    </a>",
"    ). Although the diagnosis may be evident after radiographic and endoscopic evaluation, it may not be possible to distinguish the tissue origin of a malignant periampullary neoplasm until resection and histopathologic evaluation of the entire surgical specimen is completed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=see_link&amp;anchor=H7#H7\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\", section on 'Diagnostic evaluation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not possible to reliably diagnose a patient with pancreatic cancer based on symptoms and signs alone. The lack of specificity for the diagnosis of pancreatic cancer when based on symptoms that are highly suggestive and sensitive for pancreatic cancer was shown in a landmark study in which 57 percent of such patients had other diagnoses, including non-pancreatic intraabdominal cancers (13 percent), pancreatitis (12 percent), and non-pancreatic, non-cancerous disorders including irritable bowel syndrome (23 percent) and miscellaneous other conditions (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Awareness of risk factors (genetic predisposition, age, smoking, diabetes) may lead to an earlier and more aggressive evaluation for pancreatic cancer in patients who present with symptoms suspicious for the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the diagnostic evaluation of a patient with suspected pancreatic cancer includes serologic evaluation and abdominal imaging. Additional testing is then directed based upon the findings of the initial testing as well as the patient&rsquo;s clinical presentation and risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747298\">",
"    <span class=\"h2\">",
"     Initial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients presenting with jaundice or epigastric pain should have an assay of serum aminotransferases, alkaline phosphatase, and bilirubin to determine if cholestasis is present. In addition, patients with epigastric pain should be evaluated for acute pancreatitis with a serum lipase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Screening laboratory studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Epigastric pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The next step in the patient&rsquo;s evaluation is abdominal imaging, though the choice of test varies depending upon the patient&rsquo;s presenting symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163255339\">",
"    <span class=\"h3\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with jaundice, the initial imaging study is typically a transabdominal ultrasound (US). Transabdominal US has high sensitivity for detecting biliary tract dilation and establishing the level of obstruction. It also has high sensitivity (&gt;95 percent) for detecting a mass in the pancreas, although sensitivity is lower for tumors &lt;3 cm. (See",
"    <a class=\"local\" href=\"#H163254646\">",
"     'Transabdominal ultrasound'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in some patients the first test obtained may be an endoscopic retrograde cholangiopancreatography (ERCP) or a magnetic resonance cholangiopancreatography (MRCP). This most often occurs in a patient in whom there is a high suspicion for choledocholithiasis. However, because of the increased cost and risks associated with these procedures, transabdominal US is preferred as the initial imaging study for patients suspected of having pancreatic cancer. (See",
"    <a class=\"local\" href=\"#H21056075\">",
"     'ERCP'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\", section on 'Indications for ERCP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=see_link&amp;anchor=H4#H4\">",
"     \"Magnetic resonance cholangiopancreatography\", section on 'Clinical use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163255347\">",
"    <span class=\"h3\">",
"     Epigastric pain and weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal computed tomography (CT) is the preferred initial imaging test in patients presenting with epigastric pain and weight loss, but without jaundice. (See",
"    <a class=\"local\" href=\"#H163255596\">",
"     'Abdominal CT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In practice, transabdominal US is commonly utilized as an initial screening technique for biliary-pancreatic disease in such patients because of to its low cost and wide availability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, while transabdominal ultrasound has high sensitivity for detecting tumors &gt;3 cm, it is much lower for smaller tumors. (See",
"    <a class=\"local\" href=\"#H163254646\">",
"     'Transabdominal ultrasound'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, if acute pancreatitis is in the differential, transabdominal US is not the preferred initial test. It is associated with a high frequency of incomplete examinations owing to overlying bowel gas from an ileus, and it cannot clearly identify necrosis within the pancreas; these important findings are best seen by contrast enhanced CT scan.",
"   </p>",
"   <p>",
"    For these reasons, and because of the greater amount of staging information that can be obtained, CT is preferred in this setting, particularly for patients who have symptoms other than epigastric pain that raise suspicion for pancreatic cancer (eg, weight loss, recent diagnosis of atypical diabetes mellitus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical presentation'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163255239\">",
"    <span class=\"h3\">",
"     Subsequent testing if initial imaging is positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a pancreatic mass is seen on transabdominal US, an abdominal CT scan is typically obtained to confirm the presence of the mass and to assess disease extent. If the CT appearance is typical, enough information is provided to assess resectability, and the patient is fit for a major operation, additional testing (including biopsy) may be unnecessary before surgical intervention. On the other hand, if the diagnosis is in doubt, resectability is uncertain, or if a therapeutic intervention is needed, additional procedures may be indicated. (See",
"    <a class=\"local\" href=\"#H18017084\">",
"     'Staging system and the staging workup'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2363341\">",
"     'Diagnostic algorithm and need for preoperative biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ERCP is indicated if choledocholithiasis remains in the differential diagnosis after initial evaluation or if biliary decompression is required. However, not all patients with biliary obstruction from pancreatic cancer require decompression, and stent placement should be avoided in patients who have not yet undergone CT because a stent may cause artifact in the pancreatic head that can mask the lesion, and the trauma of stent insertion may induce inflammatory changes that might be indistinguishable from tumor. (See",
"    <a class=\"local\" href=\"#H21056075\">",
"     'ERCP'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRCP is an alternative for patients who cannot undergo ERCP (eg, those with a gastric outlet obstruction), but it lacks therapeutic capability. (See",
"    <a class=\"local\" href=\"#H1617931\">",
"     'MRCP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    EUS-guided or percutaneous biopsies of a pancreatic mass can be obtained if histologic confirmation is needed, though this is not always required in patients who appear to have potentially resectable disease and who have typical imaging findings. EUS may also be used as an alternative to contrast-enhanced triple-phase helical CT for the staging of pancreatic cancer. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'EUS'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2362725\">",
"     'Biopsy and establishing the diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747860\">",
"    <span class=\"h3\">",
"     Subsequent testing if initial imaging is negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are strongly suspected of having pancreatic cancer but whose initial imaging is negative, further testing may be indicated. If an abdominal CT scan has not yet been done, that is the next step.",
"   </p>",
"   <p>",
"    For patients with cholestasis who have only had transabdominal US, ERCP is indicated. MRCP is an alternative for patients who cannot undergo ERCP (eg, those with a gastric outlet obstruction). (See",
"    <a class=\"local\" href=\"#H163255339\">",
"     'Jaundice'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1617931\">",
"     'MRCP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If these tests are negative, additional testing is typically not required and an alternative cause for the patient&rsquo;s symptoms should be sought. However, if the suspicion for pancreatic cancer remains high (eg, in a patient with profound weight loss or who has risk factors for pancreatic cancer, such as hereditary pancreatitis or chronic pancreatitis), an EUS is a reasonable next step to exclude a small pancreatic cancer (",
"    <a class=\"graphic graphic_algorithm graphicRef82523 \" href=\"mobipreview.htm?35/37/36432\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any lesions that are visible only on EUS should be biopsied to confirm the diagnosis prior to surgical exploration. EUS-guided fine needle aspiration biopsy is the best modality for obtaining a tissue diagnosis, even if the tumor is poorly visualized by other imaging modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158747285\">",
"    <span class=\"h2\">",
"     Specific tests used in the initial evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163254646\">",
"    <span class=\"h3\">",
"     Transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial study in patients who present with obstructive jaundice or epigastric pain and weight loss is often transabdominal ultrasound (US). Transabdominal US has high sensitivity for detecting biliary tract dilation and establishing the level of obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On US, a pancreatic carcinoma typically appears as a focal hypoechoic hypovascular solid mass with irregular margins. Dilated bile ducts may also suggest the presence of a pancreatic tumor.",
"   </p>",
"   <p>",
"    Support for the utility of first-line abdominal US for the diagnosis of a pancreatic tumor in patients who present with symptoms of pancreatic cancer comes from a prospective cohort study of 900 patients who underwent transabdominal US to work up painless jaundice, anorexia, or unexplained weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/28\">",
"     28",
"    </a>",
"    ]. The sensitivity for detection of all tumors in the pancreas was 89 percent (124 of 140), including 90 percent for detection of exocrine pancreatic cancer (79 of 88 patients). Among the 779 patients who were followed over time and established not to have developed a pancreatic tumor, nine had false-positive US findings (specificity 99 percent).",
"   </p>",
"   <p>",
"    While the reported sensitivity for US in diagnosing pancreatic cancer is 95 percent for tumors &gt;3 cm, it is much less for smaller tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/21,28,29\">",
"     21,28,29",
"    </a>",
"    ]. Sensitivity is also dependent upon the expertise of the ultrasonographer and the presence or absence of bile duct obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163255596\">",
"    <span class=\"h3\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mass within the pancreas is the most common CT finding of pancreatic cancer, although enlargement of the whole gland is sometimes seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. Sensitivity of CT for pancreatic cancer depends on technique and is highest (89 to 97 percent) with triple-phase, helical multidetector row CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/31\">",
"     31",
"    </a>",
"    ]. As expected, sensitivity is higher for larger tumors; in one study, the sensitivity was 100 percent for tumors &gt;2 cm, but only 77 percent for tumors &le;2 cm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/32\">",
"     32",
"    </a>",
"    ]. This &ldquo;pancreatic protocol&rdquo; type of CT is often not the initial study for a patient without a known diagnosis of pancreatic cancer. (See",
"    <a class=\"local\" href=\"#H11417555\">",
"     'Technique'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H158747298\">",
"     'Initial testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The typical CT appearance of an exocrine pancreatic cancer is an ill-defined hypoattenuating mass within the pancreas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62281 \" href=\"mobipreview.htm?32/59/33718\">",
"     image 1",
"    </a>",
"    ), although smaller lesions may be isoattenuating, making their identification difficult, particularly on non-contrast CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary signs of a pancreatic cancer (which are seen with many small isoattenuating cancers) include a pancreatic duct cutoff, dilatation of the pancreatic duct or common bile duct, parenchymal atrophy, and contour abnormalities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56487 \" href=\"mobipreview.htm?27/9/27794\">",
"     image 2",
"    </a>",
"    ). Dilation of both the pancreatic duct and the common bile duct, commonly referred to as the &ldquo;double duct sign&rdquo; is present in about 62 to 77 percent of cases of pancreatic cancer (",
"    <a class=\"graphic graphic_picture graphicRef86180 \" href=\"mobipreview.htm?32/28/33220\">",
"     picture 1",
"    </a>",
"    ), but is not diagnostic for a pancreatic head malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Approximately 50 percent of ampullary carcinomas have a double duct sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/36\">",
"     36",
"    </a>",
"    ], and it can also occasionally be seen with benign adenomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21056075\">",
"    <span class=\"h3\">",
"     ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is a highly sensitive tool for visualization of the biliary tree and pancreatic ducts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19816?source=see_link&amp;anchor=H2#H2\">",
"     \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\", section on 'Endoscopic retrograde cholangiopancreatography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early meta-analysis found a sensitivity of 92 percent and specificity of 96 percent for diagnosing cancer of the pancreas by ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/37\">",
"     37",
"    </a>",
"    ]. Findings suggestive of a malignant tumor within the head of the pancreas include superimposable strictures or obstruction of the common bile and pancreatic ducts (the \"double duct\" sign), a pancreatic duct stricture in excess of 1 cm in length, pancreatic duct obstruction, and the absence of changes suggestive of chronic pancreatitis (",
"    <a class=\"graphic graphic_picture graphicRef86180 \" href=\"mobipreview.htm?32/28/33220\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Furthermore, ERCP provides an opportunity to collect tissue samples (forceps biopsy, brush cytology) for histologic diagnosis. However, the sensitivity for detection of malignancy (approximately 50 to 60 percent) is lower than that of endoscopic ultrasound (EUS)-guided FNA (sensitivity 92 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19816?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\", section on 'Tissue sampling during ERCP'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2363690\">",
"     'EUS-guided biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other limitations of ERCP are that parenchymal abnormalities can only be detected by inference; tumors can be missed in the uncinate process, accessory duct, and tail; and the need for intraductal contrast administration. Direct visualization of the pancreatic duct is possible during ERCP using pancreatoscopy. Pancreatoscopy uses a miniature endoscope that is passed through the duodenoscope (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75248 \" href=\"mobipreview.htm?0/60/965\">",
"     image 3",
"    </a>",
"    ) to visualize the pancreatic duct and to obtain targeted biopsies of pancreatic duct strictures. However, the procedure is not widely available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ERCP is superior to transabdominal US and CT for the detection of extrahepatic biliary obstruction, and is the procedure of choice when there is suspicion for choledocholithiasis. However, it is also more expensive than ultrasound or CT, and as an invasive procedure, it is associated with a finite rate of mortality (0.2 percent) and complications such as pancreatitis, bleeding, and cholangitis. As a result, the role of ERCP in patients with suspected pancreatic cancer is evolving into a mainly therapeutic modality for patients who present with cholestasis due to tumor obstruction of the biliary system and require placement of a biliary stent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\", section on 'Endoscopic retrograde cholangiopancreatography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, preoperative stenting is not always necessary in a patient with a potentially resectable pancreatic cancer, even in the presence of cholangitis. Furthermore, if it is undertaken, stenting should not be performed before CT scanning to assess resectability, as the stent may cause artifact in the pancreatic head that can mask the lesion, and the trauma of stent insertion may induce inflammatory changes that might be indistinguishable from tumor. The indications and controversies surrounding the risks and benefits of preoperative stent placement are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H7922055#H7922055\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1617931\">",
"    <span class=\"h3\">",
"     MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to diagnostic ERCP is magnetic resonance cholangiopancreatography (MRCP). MRCP uses MR technology to create a three dimensional image of the pancreaticobiliary tree, liver parenchyma, and vascular structures. MRCP is better than CT for defining the anatomy of the biliary tree and pancreatic duct, has the capability to evaluate the bile ducts both above and below a stricture, and can also identify intrahepatic mass lesions. It is at least as sensitive as ERCP in detecting pancreatic cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], and unlike conventional ERCP, it does not require contrast material to be administered into the ductal system. Thus, the morbidity associated with endoscopic procedures and contrast administration is avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although MRCP has not yet replaced ERCP in the patients suspected of having pancreatic cancer in most centers (",
"    <a class=\"graphic graphic_algorithm graphicRef82523 \" href=\"mobipreview.htm?35/37/36432\">",
"     algorithm 2",
"    </a>",
"    ), it may be preferred in specific settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have gastric outlet or duodenal stenosis or who have had surgical rearrangement (eg, Billroth II) or ductal disruption, resulting in ducts which are difficult to assess successfully by ERCP.",
"     </li>",
"     <li>",
"      To detect bile duct obstruction occurring in the setting of chronic pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=see_link\">",
"       \"Complications of chronic pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients in whom attempted ERCP is either totally unsuccessful or provides incomplete information because of pancreatic duct obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620032\">",
"    <span class=\"h3\">",
"     Role of tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several serum markers for pancreatic cancer have been evaluated, the most useful of which is cancer-associated antigen 19-9 (CA 19-9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620046\">",
"    <span class=\"h4\">",
"     CA 19-9",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported sensitivity and specificity rates of CA 19-9 for pancreatic cancer range from 70 to 92, and 68 to 92 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. However, sensitivity is closely related to tumor size. CA 19-9 levels are of limited sensitivity for small cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/41,46-49\">",
"     41,46-49",
"    </a>",
"    ]. Furthermore, CA 19-9 requires the presence of the Lewis blood group antigen (a glycosyl transferase) to be expressed. Among individuals with a Lewis-negative phenotype (an estimated 5 to 10 percent of the population), CA 19-9 levels are not a useful tumor marker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/48,50\">",
"     48,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CA 19-9 levels also have low specificity. CA 19-9 is frequently elevated in patients with cancers other than pancreatic cancer and various benign pancreaticobiliary disorders (",
"    <a class=\"graphic graphic_table graphicRef52557 \" href=\"mobipreview.htm?3/11/3259\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/46-48,51,52\">",
"     46-48,51,52",
"    </a>",
"    ]. One study found that serum concentrations above 37",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    represented the most accurate cutoff value for discriminating pancreatic cancer from benign pancreatic disease, but the sensitivity and specificity for pancreatic cancer at this level were only 77 and 87 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/51\">",
"     51",
"    </a>",
"    ]. Furthermore, the positive predictive value (PPV) is low, particularly among asymptomatic individuals. In a large series of over 70,000 asymptomatic individuals, the PPV of a serum level &gt;37",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    was only 0.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/53\">",
"     53",
"    </a>",
"    ]. Because of this, expert guidelines recommend against the use of CA 19-9 as a screening test for pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/54\">",
"     54",
"    </a>",
"    ]. Even among symptomatic individuals (epigastric pain, weight loss, jaundice), the sensitivity, specificity, and positive predictive value of an elevated CA 19-9 &gt;37",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    level are only approximately 80, 85, and 72 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/47,55\">",
"     47,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specificity and PPV for the diagnosis of pancreatic cancer can be improved by using higher cutoff levels (100 or even 1000",
"    <span class=\"nowrap\">",
"     U/mL),",
"    </span>",
"    but at the expense of sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/47\">",
"     47",
"    </a>",
"    ]. Importantly, there is a very broad range of CA 19-9 levels that can be seen in benign disease, and there are no specific cutoff values (even beyond 10,000",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    that are seen only in patients with malignant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/44,51,56\">",
"     44,51,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of CA 19-9 do have some value as prognostic markers and also as an indicator of disease activity in patients with initially elevated levels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of elevation of CA 19-9 (both at initial presentation and in the postoperative setting) is associated with long-term prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/57-62\">",
"       57-62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients who appear to have potentially resectable pancreatic cancer, the magnitude of the preoperative CA 19-9 level can also help to predict the presence of radiographically occult metastatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/57,63-66\">",
"       57,63-66",
"      </a>",
"      ]. As an example, in a report of 491 patients undergoing staging laparoscopy for a radiographically resectable pancreatic adenocarcinoma, CA 19-9 values above 130",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      were a significant predictor of radiographically occult unresectable disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/63\">",
"       63",
"      </a>",
"      ]. The rates of unresectable disease among all patients with a CA 19-9 level &ge;130",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      versus &lt;130",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      were 26 and 11 percent, respectively. Among patients with tumors in the",
"      <span class=\"nowrap\">",
"       body/tail",
"      </span>",
"      of the pancreas, more than one-third of those who had a CA 19-9 level &ge;130",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      had unresectable disease.",
"      <br/>",
"      <br/>",
"      While high levels of CA 19-9 levels may help surgeons to better select patients for staging laparoscopy, an expert panel convened by the American Society of Clinical Oncology (ASCO) recommended against the use of CA 19-9 alone as an indicator of operability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial monitoring of CA 19-9 levels (once every one to three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/54\">",
"       54",
"      </a>",
"      ]) is useful to follow patients after potentially curative surgery and for those who are receiving chemotherapy for advanced disease. Rising CA 19-9 levels usually precede the radiographic appearance of recurrent disease, but confirmation of disease progression should be pursued with imaging studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link&amp;anchor=H4#H4\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'CA 19-9 level'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620094\">",
"    <span class=\"h4\">",
"     Other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several marker candidates have emerged from preclinical studies (and one, macrophage inhibitory cytokine-1, appears particularly promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/67\">",
"     67",
"    </a>",
"    ]), none has replaced CA 19-9 to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2362725\">",
"    <span class=\"h2\">",
"     Biopsy and establishing the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic confirmation is required to establish a diagnosis of pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the initial evaluation, some patients may have a biopsy-proven diagnosis of pancreatic cancer, typically because they presented with jaundice and underwent an ERCP. (See",
"    <a class=\"local\" href=\"#H21056075\">",
"     'ERCP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in many cases, the diagnosis will not yet be histologically confirmed. Once pancreatic cancer is suspected on initial imaging studies, the next step in the workup is generally a staging evaluation to establish disease extent and resectability rather than biopsy. Patients who are fit for major surgery and who appear to have potentially resectable pancreatic cancer after the staging evaluation is complete do not necessarily need a preoperative biopsy confirming the diagnosis of a pancreatic cancer before proceeding directly to surgery. However, the increased recognition of chronic or autoimmune pancreatitis, which can closely mimic pancreatic cancer, has altered this paradigm in certain populations. A preoperative biopsy may be recommended if a diagnosis of chronic or autoimmune pancreatitis is suspected on the basis of history (eg, extreme young age, prolonged ethanol abuse, history of other autoimmune diseases), particularly if imaging studies (EUS, ERCP or magnetic resonance cholangiopancreatography) reveal multifocal biliary strictures (suggestive of autoimmune pancreatitis) or diffuse pancreatic ductal changes (suggestive of chronic pancreatitis). These issues are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H2363341\">",
"     'Diagnostic algorithm and need for preoperative biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When it is indicated, biopsy of a pancreatic mass can be accomplished either percutaneously or via EUS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2362986\">",
"    <span class=\"h3\">",
"     Percutaneous biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous fine needle aspiration (FNA) biopsy of a pancreatic mass can be performed using either ultrasound or computed tomographic (CT) guidance (",
"    <a class=\"graphic graphic_picture graphicRef82554 \" href=\"mobipreview.htm?3/18/3375\">",
"     picture 2",
"    </a>",
"    ). The sensitivity and specificity of this procedure for the diagnosis of pancreatic cancer depends upon tumor size and operator expertise; values in the range of 80 to 90 and 98 to 100 percent, respectively, are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A theoretical concern is that percutaneous FNA biopsy of the pancreas may disseminate tumor cells intraperitoneally or along the needle path in patients who are believed to be candidates for potentially curative resection. However, the risk appears to be quite low or absent. In one study of 41 patients undergoing resection for primary pancreatic adenocarcinoma, 21 of 32 patients without preoperative open biopsies had undergone preoperative CT or fluoroscopically guided FNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/69\">",
"     69",
"    </a>",
"    ]. There was no increase in positive peritoneal washings, peritoneal failure rate, or median survival in these patients. Nevertheless, concern persists and, in practice, we try to avoid percutaneous FNA in patients with resectable masses.",
"   </p>",
"   <p>",
"    A transduodenal EUS-guided FNA biopsy or ERCP sampling reduces these risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21056075\">",
"     'ERCP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2363690\">",
"    <span class=\"h3\">",
"     EUS-guided biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-guided FNA is the best modality for obtaining a tissue diagnosis, even if the tumor is poorly visualized by other imaging modalities. This procedure is less likely to cause intraperitoneal spread of the tumor since the biopsy is obtained through the bowel wall rather than percutaneously. EUS-guided FNA has a sensitivity of approximately 90 percent and specificity of 96 percent for the diagnosis of a pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link&amp;anchor=H18#H18\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\", section on 'Accuracy of EUS-FNA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of molecular genetic analysis (eg, assay for K-ras or p53 gene mutations by RT-PCR) to cytologic examination may improve sensitivity, especially in patients with small primary tumors. At present, however, molecular analysis is not a routine component of the diagnostic evaluation for pancreatic masses. EUS-guided FNA is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link&amp;anchor=H16#H16\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\", section on 'EUS-FNA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If FNA specimens are inadequate or non-diagnostic, EUS-guided trucut (core needle) biopsy may be considered, where local expertise is available. At some institutions, a trucut biopsy may be preferred over FNA for the evaluation of solid pancreatic mass lesions that are accessible from the stomach, in the absence of a contraindication (accessible target, lack of intervening structures prohibiting biopsy, uncorrectable coagulopathy or thrombocytopenia, uncooperative patient). The role of EUS-guided trucut biopsy in the evaluation of pancreatic masses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14471?source=see_link\">",
"     \"Endoscopic ultrasound guided trucut biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18017084\">",
"    <span class=\"h1\">",
"     STAGING SYSTEM AND THE STAGING WORKUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred staging system for all pancreatic cancers (exocrine and neuroendocrine) is the tumor-node-metastasis system of the combined American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/73\">",
"     73",
"    </a>",
"    ]. The goal of the staging workup is to delineate the extent of disease spread and identify patients who are eligible for resection with curative intent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies play an important role in the staging and management of pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18176032\">",
"    <span class=\"h3\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT provides an assessment of local and regional disease extent, which determines resectability, and also evaluates the possibility of distant metastatic spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11417555\">",
"    <span class=\"h4\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reliability of CT as a staging tool for pancreatic cancer is highly dependent upon technique. Triple-phase contrast-enhanced thin-slice (multidetector row) helical computed tomography (MDCT) with three dimensional reconstruction is the preferred method to diagnose and stage pancreatic cancer. Helical CT scanners with multiple rows of detectors permit imaging of larger volumes of tissue while acquiring both arterial and venous phases in shorter periods of time (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. This has improved the evaluation of the main pancreatic duct and, thus, the detection of small tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For comprehensive imaging of a suspected pancreas cancer, the patient is usually scanned in several dynamic phases of contrast injection (termed a &ldquo;pancreas protocol&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arterial phase of enhancement, which corresponds to the first 30 seconds after the start of the contrast injection, provides excellent opacification of the celiac axis, superior mesenteric artery (SMA), and peripancreatic arteries.",
"     </li>",
"     <li>",
"      An attenuation difference between tumor and normal pancreas, which increases lesion conspicuity, is best achieved after peak enhancement of the aorta in the arterial phase but before peak enhancement of the liver, which occurs in the portal venous phase. This is sometimes termed the &ldquo;pancreatic phase&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/78,79\">",
"       78,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The portal venous phase, which is obtained at 60 to 70 seconds after the start of the contrast injection, provides better enhancement of the superior mesenteric vein, splenic and portal veins. In addition, peak hepatic enhancement, which optimizes the detection of hepatic metastases, also occurs in the portal venous phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Assessing resectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical resection is the only potentially curative modality of treatment for pancreatic cancer. An initial assessment of resectability can usually be made based upon the preoperative triple-phase staging contrast-enhanced CT scan. Local unresectability is usually (but not always) due to vascular invasion, particularly of the superior mesenteric artery (SMA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1472388\">",
"    <span class=\"h5\">",
"     Definitions of unresectable and borderline resectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although practice is variable across institutions, many surgeons would consider a pancreatic cancer to be categorically unresectable if any of the following are present (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\", section on 'Criteria for unresectability'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrapancreatic involvement, including extensive peripancreatic lymphatic involvement, nodal involvement beyond the peripancreatic tissues,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distant metastases.",
"     </li>",
"     <li>",
"      Direct involvement of the superior mesenteric artery (SMA), inferior vena cava, aorta, celiac axis, or hepatic artery, as defined by the absence of a fat plane between the low density tumor and these structures on CT scan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is less consensus on the definition of \"borderline\" resectable pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Some reserve the term \"borderline resectable\" for cases where there is focal (less than one-half of the circumference) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50998 \" href=\"mobipreview.htm?21/47/22263\">",
"     image 4",
"    </a>",
"    ) tumor abutment of the visceral arteries or short-segment occlusion of the superior mesenteric vein (SMV) or",
"    <span class=\"nowrap\">",
"     SMV/portal",
"    </span>",
"    vein confluence or hepatic artery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\", section on 'Borderline resectable'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Encasement (more than one-half of the vessel circumference) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50998 \" href=\"mobipreview.htm?21/47/22263\">",
"     image 4",
"    </a>",
"    ) or",
"    <span class=\"nowrap\">",
"     occlusion/thrombus",
"    </span>",
"    of the superior mesenteric vein (SMV) or the SMV-portal vein confluence used to be universally considered an indicator of unresectability. However, many centers have demonstrated the feasibility of SMV reconstruction, and this is now considered by many to also represent borderline resectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/84\">",
"     84",
"    </a>",
"    ]. If venous occlusion is present, a suitable segment of portal vein (above) and SMV (below the site of venous involvement) must be present to allow for venous reconstruction. However, in most centers, surgery will be preceded by some form of neoadjuvant treatment for patients with venous occlusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\", section on 'Borderline resectable'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H436301373#H436301373\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Vascular resection'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    considers the following to represent criteria for borderline resectable disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For tumors of the head or body:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe unilateral or bilateral SMV or portal infringement",
"     </li>",
"     <li>",
"      Less than one-half the circumference (180 degree) tumor abutment on the SMA",
"     </li>",
"     <li>",
"      Abutment or encasement of the hepatic artery, if reconstructible",
"     </li>",
"     <li>",
"      Short segment SMV occlusion, if there is an adequate segment of vein above and below the site of tumor involvement to allow for venous resection and reconstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For tumors of the tail:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 180 degree encasement of the SMA or celiac artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, patients with borderline resectable disease are referred for neoadjuvant therapy prior to surgical exploration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The entire concept of a &ldquo;borderline resectable&rdquo; pancreatic cancer is problematic for centers trying to accurately stage and treat patients according to the AJCC staging system. The AJCC uses the T4 category (tumor involves the celiac axis or the superior mesenteric artery) to designate an unresectable primary tumor, with T3 designating a tumor that extends beyond the pancreas but without involvement of the celiac axis or mesenteric artery. However, as noted above, involvement of a focal area of the visceral arteries may be considered a borderline resectable situation. One study of 257 patients with stage III pancreatic cancer (all T4 lesions based upon infiltration of the celiac axis or SMA) found that 30 percent could undergo a successful complete (R0) resection after chemoradiation or chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/85\">",
"     85",
"    </a>",
"    ]. Revisions to the AJCC staging system are anticipated. (See",
"    <a class=\"local\" href=\"#H18017084\">",
"     'Staging system and the staging workup'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1472545\">",
"    <span class=\"h5\">",
"     Accuracy of CT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary tumor &ndash;",
"      </strong>",
"      The sensitivity of triple-phase helical CT for pancreatic adenocarcinoma is high, 89 to 97 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/31\">",
"       31",
"      </a>",
"      ]. As expected, sensitivity is higher for larger tumors; in one study, the sensitivity was 100 percent for tumors &gt;2 cm, but only 77 percent for tumors &le;2 cm in size [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/32\">",
"       32",
"      </a>",
"      ]. However, most small isoattenuating pancreatic cancers have secondary signs such as a pancreatic duct cutoff or dilated main pancreatic duct [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Metastatic disease &ndash;",
"      </strong>",
"      Contrast-enhanced CT is the modality of choice to detect distant metastases (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63442 \" href=\"mobipreview.htm?11/58/12198\">",
"       image 5",
"      </a>",
"      ). The sensitivity for hepatic metastases is high, particularly using the pancreatic protocol technique. In one study of 43 patients with pancreatic cancer, the sensitivity, specificity, positive predictive value, and negative predictive value of contrast-enhanced multidetector row helical CT for detection of liver metastases were 88, 89, 92 and 84 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/86\">",
"       86",
"      </a>",
"      ]. Lower sensitivity rates (53 and 69 percent) are reported by others and may be related to the size of the hepatic metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Peritoneal involvement may be detected indirectly by the presence of ascites, mesenteric nodules, or mesenteric lymph nodes. However, the sensitivity of CT for peritoneal dissemination is poor and not sufficiently high to eliminate the need for diagnostic laparoscopy in equivocal cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/89-91\">",
"       89-91",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1618421\">",
"       'Staging laparoscopy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      For tumors of the head and neck of the pancreas, regional lymphatic tumor spread usually occurs around the celiac axis and the peripancreatic and periportal areas. For tumors arising in the tail, regional nodal basins are located along the common hepatic artery, celiac axis, splenic artery and splenic hilum.",
"      <br/>",
"      <br/>",
"      The sensitivity and specificity of CT for detecting involvement of lymph nodes is low, leading some to suggest that in a patient who has a presumed pancreatic cancer that is considered resectable, the finding of peripancreatic nodes on CT should not prevent exploration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/92\">",
"       92",
"      </a>",
"      ]. However, the presence of extensive peripancreatic lymphatic involvement and nodal involvement beyond the peripancreatic tissues is generally considered to represent unresectable disease. (See",
"      <a class=\"local\" href=\"#H1472388\">",
"       'Definitions of unresectable and borderline resectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Vascular invasion &ndash;",
"      </strong>",
"      CT criteria for vascular invasion include arterial embedment in the tumor mass or venous obliteration, tumor involvement exceeding one-half the circumference of the vessel, vessel wall irregularity, vessel caliber stenosis, or a &ldquo;teardrop&rdquo; sign of the superior mesenteric vein (SMV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/93\">",
"       93",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The most commonly used system for predicting vascular invasion by a pancreatic cancer uses a five-grade scale, which is based upon the degree of contact between the tumor and the blood vessel (",
"      <a class=\"graphic graphic_table graphicRef83537 \" href=\"mobipreview.htm?33/60/34763\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/94\">",
"       94",
"      </a>",
"      ]. In the initial report of 25 patients, tumor contiguity with &gt;50 percent or more of the perimeter of the vessel was found to be the optimal threshold for predicting vascular invasion, with a sensitivity of 84 percent and a specificity of 98 percent.",
"      <br/>",
"      <br/>",
"      However, these criteria were applied equally to venous and arterial structures. As noted above, because of advances in venous reconstruction, many institutions do not consider involvement of more than one-half of the circumference of the superior mesenteric vein (SMV) or the SMV-portal vein confluence to represent unresectable disease. (See",
"      <a class=\"local\" href=\"#H1472388\">",
"       'Definitions of unresectable and borderline resectable disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Modifications of this grading system have been proposed, to increase the sensitivity for detecting venous invasion and specificity for detecting arterial invasion, but none is in widespread use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/93,95-97\">",
"       93,95-97",
"      </a>",
"      ]. High sensitivity for venous invasion is desirable so that patients with undiagnosed venous invasion will not be deemed unresectable intraoperatively if resection is attempted at an institution where venous reconstruction is not performed. On the other hand, high specificity for arterial invasion is desirable to minimize the risk of overstaging T3 disease, which may deny some patients a chance for potentially curative surgical resection.",
"      <br/>",
"      <br/>",
"      In general, helical CT has a high predictive value for unresectability (90 to 100 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/95,98-100\">",
"       95,98-100",
"      </a>",
"      ], but the predictive value for resectability is slightly lower (range 64 to 90 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/94,95,101\">",
"       94,95,101",
"      </a>",
"      ]. The accuracy of MDCT for assessing vascular invasion was addressed in a systematic review and meta-analysis of 18 studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/102\">",
"       102",
"      </a>",
"      ]. The pooled sensitivity and specificity for diagnosing vascular invasion were 77 and 81 percent, respectively, but when the analysis was limited to the five most recent studies conducted since 2004, and presumably using the most advanced CT technology, sensitivity and specificity rates were 85 and 82 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1472183\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other imaging modalities, including endoscopic ultrasound (EUS), MRI, FDG-PET as well as staging laparoscopy, may be required to assess resectability in some circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the small distance between the echoendoscope and the pancreas through the gastric or duodenal wall, endoscopic ultrasound (EUS) provides much higher resolution than transabdominal ultrasound. Pancreatic cancer on EUS appears as a hypoechoic mass, typically with dilation of the proximal pancreatic duct. The border of the lesion may have an irregular contour, and the echo pattern of the mass may be homogenous or inhomogeneous. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8884?source=see_link\">",
"     \"Endoscopic ultrasound: Normal pancreaticobiliary anatomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies comparing EUS with other imaging modalities for initial diagnosis and staging of pancreatic cancer concluded that EUS may be more accurate for smaller tumors, for local T and N staging, and for predicting vascular invasion. EUS may detect metastatic disease in the liver or mediastinal lymph nodes, but is inferior to CT for evaluation of distant metastases. In addition, the specificity of EUS is limited, particularly when inflammatory changes are present. EUS is also operator-dependent; as a result, its value varies with locally available expertise. The development of modern multidetector row CT has markedly improved the sensitivity of CT for the detection of smaller tumors and the presence of vascular invasion, reaching values that are comparable to those obtained by EUS by an experienced endoscopist. However, head-to-head studies comparing the two modalities are lacking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link&amp;anchor=H10#H10\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\", section on 'Comparison of EUS with other imaging techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of EUS in the preoperative staging of pancreatic cancer is evolving, and there are several points in the diagnostic evaluation where this modality may be of benefit, particularly for patients whose CT evaluation does not demonstrate a defined mass lesion (",
"    <a class=\"graphic graphic_algorithm graphicRef82523 \" href=\"mobipreview.htm?35/37/36432\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H158747860\">",
"     'Subsequent testing if initial imaging is negative'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, EUS-guided fine needle aspiration biopsy (FNA) is the best modality for obtaining a tissue diagnosis, even if the tumor is poorly visualized by other imaging modalities. (See",
"    <a class=\"local\" href=\"#H2363690\">",
"     'EUS-guided biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pancreatic adenocarcinomas are easily visualized on MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55392 \" href=\"mobipreview.htm?37/15/38133\">",
"     image 6",
"    </a>",
"    ), there is no evidence that MRI offers a significant diagnostic advantage over triple-phase MDCT for the local staging evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/103-107\">",
"     103-107",
"    </a>",
"    ]. One potential benefit of MRI is its increased sensitivity for the detection of small liver metastases compared with CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/87,88,108,109\">",
"     87,88,108,109",
"    </a>",
"    ]. Combining CT and MRI offers little that cannot be achieved with one alone. Thus, the choice of MRI or CT depends upon the level of locally available expertise and the clinician's comfort with one or the other radio-imaging technique. We prefer MDCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937783\">",
"    <span class=\"h4\">",
"     Chest CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT of the chest may be used as a staging tool to detect lung metastases. However, most centers to not perform a routine staging chest CT for patients suspected of having pancreatic cancer because in the presence of lung metastases, the primary tumor is usually unresectable for another reason [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scanning with the tracer 18-fluorodeoxyglucose (FDG) relies upon functional activity to differentiate metabolically active proliferative lesions such as cancers, most of which are FDG-avid, from benign masses. Most benign lesions do not accumulate FDG, with the exception of inflammatory lesions such as chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of PET scans in the diagnostic and staging evaluation of suspected pancreatic cancer, particularly whether PET provides information beyond that obtained by contrast-enhanced MDCT, remains uncertain, as illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The sensitivity of integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      (which has better spatial resolution as compared to PET alone) in the initial diagnosis of pancreatic cancer ranges from 73 to 94 percent, while specificity ranges from 60 to 89 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/112-117\">",
"       112-117",
"      </a>",
"      ]. False-negative PET results can occur in hyperglycemic patients or in subcentimeter lesions, while false positive results can be seen in various inflammatory states such as pancreatitis, infected pseudocyst, or local inflammation caused by placement of a biliary stent. In studies in which the two modalities have been compared, PET does not appear to provide additional information to that derived from MDCT or MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/116-118\">",
"       116-118",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A major issue is that the CT component of integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      imaging is performed in many institutions without the use of IV contrast material, a technique that precludes the optimal detection of small tumors and metastases. Increasingly,",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is being carried out with IV contrast, but this practice is not widespread. Early results are promising using integrated PET with a contrast-enhanced CT, but further studies are needed to establish clinical value compared with MDCT alone in patients with pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/119-121\">",
"       119-121",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One possible benefit of PET is enhanced detection of small volume metastatic disease, which is often missed by CT. Unfortunately, the available data are conflicting, with some studies suggesting that PET is useful for identifying metastatic disease that is missed by CT (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55610 \" href=\"mobipreview.htm?31/9/31893\">",
"       image 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/114,116,122-124\">",
"       114,116,122-124",
"      </a>",
"      ] and others noting that PET often misses small volume metastases within the peritoneum and elsewhere, including the liver [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/111,112,125\">",
"       111,112,125",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, the clinical impact remains uncertain, as illustrated by the following reports:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One series compared integrated",
"      <span class=\"nowrap\">",
"       FDG/PET,",
"      </span>",
"      MDCT, and MRI in 38 consecutive patients suspected of having pancreatic cancer, with findings confirmed by operation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histopathologic analysis or follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/116\">",
"       116",
"      </a>",
"      ]. Among the 17 patients with advanced pancreatic adenocarcinoma,",
"      <span class=\"nowrap\">",
"       FDG-PET/CT",
"      </span>",
"      had a higher sensitivity than either MDCT or MRI (88 versus 30 and 30 percent, respectively), and the clinical management of 10 patients (26 percent) was altered by the findings on",
"      <span class=\"nowrap\">",
"       PET/CT.",
"      </span>",
"     </li>",
"     <li>",
"      In another report, 82 patients with a pancreatic mass that was suspicious for cancer underwent staging with integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      and contrast-enhanced CT of the chest, abdomen, and pelvis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/114\">",
"       114",
"      </a>",
"      ]. The sensitivity for detecting metastatic disease for",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      alone, CT alone, and combined CT plus integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      was 61, 57, and 87 percent, respectively. However, the findings on",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      changed management in only seven patients (11 percent), two because of an occult supraclavicular lymph node, two with occult liver lesions, two peritoneal implants, and one periesophageal lymph node. Two of these patients had locally advanced disease and would not have been considered for resection, even if a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      had not been done.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the data are insufficient to conclude that PET or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    provides useful information above that provided by contrast-enhanced CT. Consensus-based guidelines for staging of pancreatic cancer from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    state that the role of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    remains unclear. Definitive assessment of the role of PET as a component of the diagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    staging evaluation awaits a large prospective study designed to assess the benefit of PET (preferably integrated PET with a contrast-enhanced CT) in patients with a negative or indeterminate CT scan, with a prospectively designed cost effectiveness analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618421\">",
"    <span class=\"h2\">",
"     Staging laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate staging drives proper treatment of patients with pancreatic cancer, particularly when selecting patients for surgical resection. Because most have unresectable disease at presentation, a key goal is to avoid a futile laparotomy whenever possible.",
"   </p>",
"   <p>",
"    Currently available imaging techniques are highly accurate at predicting unresectable disease, but they fall short in predicting resectable disease, mainly because of limited sensitivity for small-volume metastatic disease. Radiographically occult subcentimeter metastases on the surface of the liver or peritoneum that are rarely visible by CT, MRI, PET, or transabdominal US may be visualized laparoscopically. Studies have consistently shown that up to one-third of patients thought to be resectable by state of the art imaging will be found to be unresectable based upon laparoscopic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/89,126-128\">",
"     89,126-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the value of staging laparoscopy is not universally accepted. While hospital stay, cost, and morbidity are reduced when an unnecessary open laparotomy is avoided for unresectable or metastatic disease, there are no controlled studies demonstrating a benefit for this procedure in patients who have undergone radiographic staging evaluation using modern high-quality imaging such as MDCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11417555\">",
"     'Technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Others suggest a selective approach to staging laparoscopy to maximize yield by limiting the procedure to those with the highest likelihood of occult metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/130\">",
"     130",
"    </a>",
"    ]. This includes patients with a tumor of the body or tail of the pancreas who appear to have potentially resectable disease by computed tomography scan (one-half of whom will have occult peritoneal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]), large (&gt;3 cm) primary tumors, any patient for whom high-quality imaging is in any way suggestive of occult metastatic disease, and those with a high initial CA 19-9 level (&gt;100",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Tumors in the body or tail'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1620046\">",
"     'CA 19-9'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We selectively use staging laparoscopy in patients with advanced vascular involvement (but not yet complete encasement or occlusion of the major vessels) and those with pancreatic body or tail lesions who are not jaundiced. Other indications for a staging laparoscopy prior to open laparotomy include a high preoperative CA 19-9 level (&gt;1000",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    and any patient for whom high-quality imaging is in any way suggestive of occult metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618501\">",
"    <span class=\"h3\">",
"     Importance of peritoneal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal washings are often obtained at the time of laparoscopy. While it would seem intuitive that patients who have positive peritoneal washings would be unlikely to benefit from radical resection of the pancreatic primary tumor, it has not been conclusively demonstrated that positive peritoneal cytology as an isolated finding adversely impacts prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]. In general, most patients who have cytologically-positive washings have other findings that suggest advanced disease and unresectability such as ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of metastases in the liver, pelvis, or omentum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/134,136,137\">",
"     134,136,137",
"    </a>",
"    ]. If these are absent, most pancreatic surgeons do not rely upon the results of peritoneal washings obtained at the time of laparoscopy to guide decision-making regarding resectability. However, the AJCC staging system considers positive peritoneal washings to represent distant metastatic (M1) disease (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2363341\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ALGORITHM AND NEED FOR PREOPERATIVE BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggested diagnostic approach to the patient with suspected pancreatic cancer is outlined in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef82523 \" href=\"mobipreview.htm?35/37/36432\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2362725\">",
"     'Biopsy and establishing the diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A diagnostic biopsy of a suspected pancreatic malignancy may be indicated if there is evidence of systemic spread of disease, if there is local evidence of unresectability on staging studies, if the patient is unfit for major surgery, if neoadjuvant treatment is being contemplated (eg, for a borderline resectable lesion), or if alternative diagnoses need to be excluded (eg, metastatic disease to the pancreas). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link&amp;anchor=H26#H26\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\", section on 'Role of surgery and management of borderline resectable disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a preoperative diagnostic biopsy may not be needed in a fit patient with a potentially resectable pancreatic lesion that is highly suspected of malignancy. While a positive biopsy can confirm the suspected diagnosis, a benign sample will not exclude the presence of malignancy. In one systematic review of 53 studies addressing this issue, the negative predictive value of percutaneous and EUS-guided biopsies was only 60 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/138\">",
"     138",
"    </a>",
"    ]. Attempts to make a preoperative tissue diagnosis may in fact be detrimental if tumor cells are disseminated during percutaneous biopsy.",
"   </p>",
"   <p>",
"    Thus, if a patient is a reasonable surgical candidate, and if the clinical presentation and imaging are typical for a resectable adenocarcinoma after the staging evaluation has been completed, it is reasonable to proceed to surgery without a tissue diagnosis. (See",
"    <a class=\"local\" href=\"#H18017084\">",
"     'Staging system and the staging workup'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, it must be recognized by both the clinician and the patient that uncertainty regarding the diagnosis in these instances persists and that some patients with benign lesions may be subjected to the radical resections used for malignant lesions. These cases comprise between 5 and 11 percent of patients resected for a presumed cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/139-142\">",
"     139-142",
"    </a>",
"    ]. The frequency of radical resection for benign disease may be reduced when this approach is combined with additional imaging, EUS-guided transduodenal biopsy. (See",
"    <a class=\"local\" href=\"#H2363690\">",
"     'EUS-guided biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Focal chronic pancreatitis and autoimmune pancreatitis are the two benign processes that are most commonly mistaken for pancreatic malignancy on CT or US. EUS-guided biopsy may be recommended if a diagnosis of chronic or autoimmune pancreatitis is suspected on the basis of history (eg, extreme young age, prolonged ethanol abuse, history of other autoimmune diseases), particularly if further imaging studies (either EUS, ERCP or magnetic resonance cholangiopancreatography) reveal multifocal biliary strictures (suggestive of autoimmune pancreatitis) or diffuse pancreatic ductal changes (suggestive of chronic pancreatitis). In addition, serologic testing can aid in the diagnosis of autoimmune pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For jaundiced patients who have no involvement or minimal involvement of the major vessels according to CT or EUS and no evidence of distant metastases on helical CT or EUS, we proceed directly to an attempt at surgical resection. For non-jaundiced patients (particularly with body or tail tumors), or those with major but incomplete involvement of the vascular structures (tumor contiguous to less than one-half of the vessel circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/40/41610/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]), we perform preoperative laparoscopy to exclude tiny metastases that might have been overlooked by CT. If the laparoscopy is negative, we then embark on a radical surgical resection. (See",
"    <a class=\"local\" href=\"#H1618421\">",
"     'Staging laparoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=see_link\">",
"       \"Patient information: Pancreatic cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The commonly used term \"pancreatic cancer\" usually refers to a ductal adenocarcinoma of the pancreas (including its subtypes). More than 95 percent of malignant neoplasms of the pancreas arise from the exocrine elements and are referred to as exocrine pancreatic cancers. (See",
"      <a class=\"local\" href=\"#H158746930\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting symptoms in patients with exocrine pancreatic cancer are pain, jaundice, and weight loss. Compared to tumors in the body and tail of the gland, pancreatic head tumors more often present with jaundice, steatorrhea, and weight loss. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present with jaundice or epigastric pain and weight loss often undergo right upper quadrant transabdominal ultrasound initially to evaluate for dilated bile ducts or a pancreatic mass. (See",
"      <a class=\"local\" href=\"#H158747298\">",
"       'Initial testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H163254646\">",
"       'Transabdominal ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the jaundiced patient, ultrasound is highly sensitive for detecting biliary tract dilation and establishing the level of obstruction; it is highly sensitive for pancreatic masses &gt;3 cm. (See",
"      <a class=\"local\" href=\"#H158747091\">",
"       'Jaundice'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Endoscopic retrograde cholangiopancreatography (ERCP) is a highly sensitive tool for visualization of the biliary tree and pancreatic ducts in patients with jaundice. However, the role of ERCP in patients with suspected pancreatic cancer is evolving into a mainly therapeutic rather than diagnostic modality in patients who present with cholestasis due to tumor obstruction of the biliary system. (See",
"      <a class=\"local\" href=\"#H21056075\">",
"       'ERCP'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      An alternative approach is magnetic resonance cholangiopancreatography (MRCP). MRCP is generally reserved for patients with gastric outlet or duodenal stenosis, or who have had surgical rearrangement (eg, Billroth II) or ductal disruption, resulting in ducts that are difficult to assess successfully by ERCP, in the setting of chronic pancreatitis, or for patients in whom attempted ERCP is either totally unsuccessful or provides incomplete information because of pancreatic duct obstruction. (See",
"      <a class=\"local\" href=\"#H1617931\">",
"       'MRCP'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      For patients with epigastric pain and weight loss without jaundice, in whom the differential diagnosis includes pancreatitis, transabdominal ultrasound is not the preferred initial test because it is associated with a high frequency of incomplete examinations owing to overlying bowel gas due to ileus, and it cannot clearly identify necrosis within the pancreas; these important findings are best seen by contrast enhanced CT scan. (See",
"      <a class=\"local\" href=\"#H163255347\">",
"       'Epigastric pain and weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic ultrasound (EUS) may be of use in a patient who is suspected of having pancreatic cancer based upon the clinical presentation of jaundice, unexplained upper abdominal",
"      <span class=\"nowrap\">",
"       pain/weight",
"      </span>",
"      loss, or an unexplained episode of pancreatitis, but who has no evidence of a mass lesion on initial transabdominal ultrasound or CT. (See",
"      <a class=\"local\" href=\"#H158747860\">",
"       'Subsequent testing if initial imaging is negative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the limited sensitivity and specificity, the serum tumor marker CA 19-9 should not be used as a diagnostic test for pancreatic cancer. (See",
"      <a class=\"local\" href=\"#H1620046\">",
"       'CA 19-9'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic confirmation is required to establish a diagnosis of pancreatic cancer. Biopsy of a pancreatic mass can be accomplished through percutaneous or endoscopic approaches. However, not all patients require a preoperative biopsy, and the next step in the workup of a patient with suspected pancreatic cancer is often a staging evaluation to establish disease extent and resectability rather than biopsy. (See",
"      <a class=\"local\" href=\"#H2362725\">",
"       'Biopsy and establishing the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a mass lesion of the pancreas is detected on CT or ultrasound, it is reasonable to conclude that a neoplasm (most likely malignant) is present, and triple-phase, contrast enhanced helical (preferably multidetector row) CT is an appropriate next step to assess disease extent and resectability. Local unresectability is usually (but not always) due to vascular invasion, particularly of the superior mesenteric artery (SMA). (See",
"      <a class=\"local\" href=\"#H18176032\">",
"       'Abdominal CT'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Endoscopic ultrasound (EUS) is another effective method to assess tumor extent and vascular invasion, but we generally prefer CT given its greater utility in assessing for distant metastases. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'EUS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although practice is variable, most surgeons would consider a pancreatic cancer to be categorically unresectable if any of the following are present (see",
"      <a class=\"local\" href=\"#H1472388\">",
"       'Definitions of unresectable and borderline resectable disease'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extensive peripancreatic lymphatic involvement, nodal involvement beyond the peripancreatic tissues,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distant metastases.",
"     </li>",
"     <li>",
"      Direct involvement of the superior mesenteric artery (SMA), inferior vena cava, aorta, celiac axis, or hepatic artery, as defined by the absence of a fat plane between the low density tumor and these structures on CT scan.",
"     </li>",
"     <li>",
"      Encasement (more than one-half of the vessel circumference) or",
"      <span class=\"nowrap\">",
"       occlusion/thrombus",
"      </span>",
"      of the superior mesenteric vein (SMV) or the SMV-portal vein confluence used to be universally considered an indicator of unresectability. However, many centers have demonstrated the feasibility of SMV reconstruction, and this is now considered by many to represent borderline resectable disease; in practice, most of these patients are referred for neoadjuvant therapy prior to surgery. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The utility of PET scans, chest CT, and MRI in the staging workup of suspected pancreatic cancer, particularly whether any of these imaging studies provides information beyond that obtained by triple-phase, contrast enhanced helical multidetector row CT remains uncertain, and we do not routinely order these tests. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'PET scanning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H937783\">",
"       'Chest CT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'MRI'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Assessment of serum levels of the tumor marker CA 19-9 prior to surgery and following resection, if elevated, is valuable to assist in prognostication. In addition, serial monitoring of CA 19-9 levels, if initially elevated, is useful to follow patients after potentially curative surgery and for those who are receiving chemotherapy for advanced disease. (See",
"      <a class=\"local\" href=\"#H1620046\">",
"       'CA 19-9'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our general diagnostic approach, as detailed in the following sections, is summarized in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef82523 \" href=\"mobipreview.htm?35/37/36432\">",
"       algorithm 2",
"      </a>",
"      ). In general (see",
"      <a class=\"local\" href=\"#H2363341\">",
"       'Diagnostic algorithm and need for preoperative biopsy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tissue diagnosis is mandatory for patients who are unfit to undergo a major resection, for those with a high suspicion of metastatic disease, and for any patient being considered for neoadjuvant therapy because of locally advanced nonmetastatic disease. EUS-guided FNA is the best modality for obtaining a tissue diagnosis, even if the tumor is poorly visualized by other imaging modalities.",
"     </li>",
"     <li>",
"      If a patient is a reasonable surgical candidate, and if the clinical presentation and imaging are typical for a resectable adenocarcinoma, it is reasonable to proceed to surgery without a tissue diagnosis.",
"      <br/>",
"      <br/>",
"      For jaundiced patients with no involvement or minimal involvement of the major vessels and no evidence of distant metastases on radiographic imaging, we proceed directly to open laparotomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For non-jaundiced patients (including all those with body or tail tumors), as well as those with major but incomplete involvement of the vascular structures (eg, tumor contiguous to less than one-half of the vessel circumference), we perform preoperative laparoscopy to exclude tiny metastases that might have been overlooked by CT. If the laparoscopy is negative, we then proceed to open laparotomy to assess resectability. Other indications for a staging laparoscopy prior to open laparotomy include a high preoperative CA 19-9 level (&gt;1000",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      and any patient for whom high-quality imaging is in any way suggestive of occult metastatic disease. (See",
"      <a class=\"local\" href=\"#H1618421\">",
"       'Staging laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/1\">",
"      Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 2005; 7:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/2\">",
"      Modolell I, Guarner L, Malagelada JR. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann Oncol 1999; 10 Suppl 4:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/3\">",
"      Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985; 56:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/4\">",
"      Bakkevold KE, Arnesj&oslash; B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol 1992; 27:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/5\">",
"      Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996; 78:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/6\">",
"      Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/7\">",
"      Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 2000; 21:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/8\">",
"      Manabe T, Miyashita T, Ohshio G, et al. Small carcinoma of the pancreas. Clinical and pathologic evaluation of 17 patients. Cancer 1988; 62:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/9\">",
"      Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol 2004; 2:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/10\">",
"      Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/11\">",
"      Aggarwal G, Kamada P, Chari ST. Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers. Pancreas 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/12\">",
"      Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/13\">",
"      Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol 1986; 4:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/14\">",
"      Ostlere LS, Branfoot AC, Staughton RC. Cicatricial pemphigoid and carcinoma of the pancreas. Clin Exp Dermatol 1992; 17:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/15\">",
"      Galva&ntilde; VG. Sister Mary Joseph's nodule. Ann Intern Med 1998; 128:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/16\">",
"      Goodman M, Willmann JK, Jeffrey RB. Incidentally discovered solid pancreatic masses: imaging and clinical observations. Abdom Imaging 2012; 37:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/17\">",
"      Stapley S, Peters TJ, Neal RD, et al. The risk of pancreatic cancer in symptomatic patients in primary care: a large case-control study using electronic records. Br J Cancer 2012; 106:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/18\">",
"      Rose JF, Jie T, Usera P, Ong ES. Pancreaticoduodenectomy for primary pancreatic lymphoma. Gastrointest Cancer Res 2012; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/19\">",
"      Rock J, Bloomston M, Lozanski G, Frankel WL. The spectrum of hematologic malignancies involving the pancreas: potential clinical mimics of pancreatic adenocarcinoma. Am J Clin Pathol 2012; 137:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/20\">",
"      DiMagno EP, Malagelada JR, Taylor WF, Go VL. A prospective comparison of current diagnostic tests for pancreatic cancer. N Engl J Med 1977; 297:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/21\">",
"      Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 1993; 25:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/22\">",
"      Tanaka S, Kitamra T, Yamamoto K, et al. Evaluation of routine sonography for early detection of pancreatic cancer. Jpn J Clin Oncol 1996; 26:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/23\">",
"      Pasanen PA, Eskelinen M, Partanen K, et al. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients. Anticancer Res 1992; 12:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/24\">",
"      Pasanen PA, Partanen KP, Pikkarainen PH, et al. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis. Eur J Surg 1993; 159:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/25\">",
"      Hessel SJ, Siegelman SS, McNeil BJ, et al. A prospective evaluation of computed tomography and ultrasound of the pancreas. Radiology 1982; 143:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/26\">",
"      Bluemke DA, Cameron JL, Hruban RH, et al. Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology 1995; 197:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/27\">",
"      Brand R. The diagnosis of pancreatic cancer. Cancer J 2001; 7:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/28\">",
"      Karlson BM, Ekbom A, Lindgren PG, et al. Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis. Radiology 1999; 213:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/29\">",
"      Maringhini A, Ciambra M, Raimondo M, et al. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 1993; 8:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/30\">",
"      Freeny PC, Marks WM, Ryan JA, Traverso LW. Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Radiology 1988; 166:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/31\">",
"      Valls C, And&iacute;a E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002; 178:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/32\">",
"      Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004; 182:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/33\">",
"      Yoon SH, Lee JM, Cho JY, et al. Small (&le; 20 mm) pancreatic adenocarcinomas: analysis of enhancement patterns and secondary signs with multiphasic multidetector CT. Radiology 2011; 259:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/34\">",
"      Nino-Murcia M, Jeffrey RB Jr, Beaulieu CF, et al. Multidetector CT of the pancreas and bile duct system: value of curved planar reformations. AJR Am J Roentgenol 2001; 176:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/35\">",
"      Fulcher AS, Turner MA. MR pancreatography: a useful tool for evaluating pancreatic disorders. Radiographics 1999; 19:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/36\">",
"      Kim JH, Kim MJ, Chung JJ, et al. Differential diagnosis of periampullary carcinomas at MR imaging. Radiographics 2002; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/37\">",
"      Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/38\">",
"      Varghese JC, Farrell MA, Courtney G, et al. Role of MR cholangiopancreatography in patients with failed or inadequate ERCP. AJR Am J Roentgenol 1999; 173:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/39\">",
"      Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/40\">",
"      Lopez H&auml;nninen E, Amthauer H, Hosten N, et al. Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 2002; 224:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/41\">",
"      Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/42\">",
"      Cwik G, Wallner G, Skoczylas T, et al. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006; 141:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/43\">",
"      van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 1996; 43:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/44\">",
"      Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/45\">",
"      Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/46\">",
"      DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999; 117:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/47\">",
"      Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/48\">",
"      Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10 Suppl 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/49\">",
"      Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005; 23:4524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/50\">",
"      Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47:5501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/51\">",
"      Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/52\">",
"      Molina V, Visa L, Conill C, et al. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol 2012; 33:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/53\">",
"      Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/54\">",
"      Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/55\">",
"      Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/56\">",
"      Marcouizos G, Ignatiadou E, Papanikolaou GE, et al. Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J 2009; 2:6662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/57\">",
"      Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005; 93:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/58\">",
"      Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26:5918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/59\">",
"      Koom WS, Seong J, Kim YB, et al. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/60\">",
"      Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010; 17:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/61\">",
"      Abdel-Misih SR, Hatzaras I, Schmidt C, et al. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol 2011; 18:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/62\">",
"      Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012; 23:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/63\">",
"      Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008; 15:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/64\">",
"      Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005; 9:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/65\">",
"      Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007; 14:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/66\">",
"      Kili&ccedil; M, G&ouml;&ccedil;men E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006; 49:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/67\">",
"      Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/68\">",
"      DelMaschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991; 178:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/69\">",
"      Johnson DE, Pendurthi TK, Balshem AM, et al. Implications of fine-needle aspiration in patients with resectable pancreatic cancer. Am Surg 1997; 63:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/70\">",
"      Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003; 58:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/71\">",
"      Chong A, Venugopal K, Segarajasingam D, Lisewski D. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. Gastrointest Endosc 2011; 74:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/72\">",
"      Paquin SC, Gari&eacute;py G, Lepanto L, et al. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc 2005; 61:610.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/74\">",
"      Horton KM, Fishman EK. Multidetector row CT with dual-phase CT angiography in the preoperative evaluation of pancreatic cancer. Crit Rev Comput Tomogr 2002; 43:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/75\">",
"      DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004; 141:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/76\">",
"      Smith SL, Rajan PS. Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol 2004; 59:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/77\">",
"      Wong JC, Raman S. Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging 2010; 35:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/78\">",
"      Lu DS, Vedantham S, Krasny RM, et al. Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Radiology 1996; 199:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/79\">",
"      Fletcher JG, Wiersema MJ, Farrell MA, et al. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 2003; 229:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/80\">",
"      Francis IR, Cohan RH, McNulty NJ, et al. Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol 2003; 180:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/81\">",
"      Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206:833.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/83\">",
"      Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/84\">",
"      Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/85\">",
"      Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, \"unresectable\" pancreatic cancer. Surgery 2012; 152:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/86\">",
"      Satoi S, Yamamoto H, Takai S, et al. Clinical impact of multidetector row computed tomography on patients with pancreatic cancer. Pancreas 2007; 34:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/87\">",
"      Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging 2011; 36:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/88\">",
"      Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011; 260:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/89\">",
"      John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 1995; 221:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/90\">",
"      Gull&agrave; N, Patriti A, Cirocchi R, et al. [The role of laparoscopy in the identification of peritoneal carcinosis from abdominal neoplasms. Analysis of our initial experience]. Minerva Chir 2000; 55:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/91\">",
"      Reddy KR, Levi J, Livingstone A, et al. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/92\">",
"      Roche CJ, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol 2003; 180:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/93\">",
"      Li H, Zeng MS, Zhou KR, et al. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005; 29:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/94\">",
"      Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997; 168:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/95\">",
"      O'Malley ME, Boland GW, Wood BJ, et al. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol 1999; 173:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/96\">",
"      Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996; 21:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/97\">",
"      Nakayama Y, Yamashita Y, Kadota M, et al. Vascular encasement by pancreatic cancer: correlation of CT findings with surgical and pathologic results. J Comput Assist Tomogr 2001; 25:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/98\">",
"      Saldinger PF, Reilly M, Reynolds K, et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000; 4:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/99\">",
"      Coley SC, Strickland NH, Walker JD, Williamson RC. Spiral CT and the pre-operative assessment of pancreatic adenocarcinoma. Clin Radiol 1997; 52:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/100\">",
"      Kaneko OF, Lee DM, Wong J, et al. Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma. J Comput Assist Tomogr 2010; 34:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/101\">",
"      Vedantham S, Lu DS, Reber HA, Kadell B. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. AJR Am J Roentgenol 1998; 170:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/102\">",
"      Zhao WY, Luo M, Sun YW, et al. Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/103\">",
"      Li KC, Hopkins KL, Dalman RL, Song CK. Simultaneous measurement of flow in the superior mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of chronic mesenteric ischemia. Work in progress. Radiology 1995; 194:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/104\">",
"      Megibow AJ, Zhou XH, Rotterdam H, et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group. Radiology 1995; 195:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/105\">",
"      Irie H, Honda H, Kaneko K, et al. Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Abdom Imaging 1997; 22:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/106\">",
"      Sheridan MB, Ward J, Guthrie JA, et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 1999; 173:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/107\">",
"      Buchs NC, Chilcott M, Poletti PA, et al. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol 2010; 16:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/108\">",
"      Trede M, Rumstadt B, Wendl K, et al. Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors. Ann Surg 1997; 226:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/109\">",
"      Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001; 38:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/110\">",
"      Nordback I, Saaristo R, Piironen A, Sand J. Chest computed tomography in the staging of pancreatic and periampullary carcinoma. Scand J Gastroenterol 2004; 39:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/111\">",
"      Singer E, Gschwantler M, Plattner D, et al. Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera. Eur J Gastroenterol Hepatol 2007; 19:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/112\">",
"      Izuishi K, Yamamoto Y, Sano T, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010; 14:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/113\">",
"      Heinrich S, Goerres GW, Sch&auml;fer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/114\">",
"      Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008; 15:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/115\">",
"      Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging 2008; 35:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/116\">",
"      Kauhanen SP, Komar G, Sepp&auml;nen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009; 250:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/117\">",
"      Lytras D, Connor S, Bosonnet L, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/118\">",
"      Nguyen NQ, Bartholomeusz DF. 18F-FDG-PET/CT in the assessment of pancreatic cancer: is the contrast or a better-designed trial needed? J Gastroenterol Hepatol 2011; 26:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/119\">",
"      Strobel K, Heinrich S, Bhure U, et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008; 49:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/120\">",
"      Buchs NC, B&uuml;hler L, Bucher P, et al. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol 2011; 26:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/121\">",
"      Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol 2010; 12:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/122\">",
"      Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000; 52:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/123\">",
"      Nishiyama Y, Yamamoto Y, Yokoe K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005; 19:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/124\">",
"      Zafra M, Ayala F, Gonzalez-Billalabeitia E, et al. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients. Eur J Cancer 2008; 44:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/125\">",
"      Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/126\">",
"      Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 2005; 19:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/127\">",
"      Thomson BN, Parks RW, Redhead DN, et al. Refining the role of laparoscopy and laparoscopic ultrasound in the staging of presumed pancreatic head and ampullary tumours. Br J Cancer 2006; 94:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/128\">",
"      Mayo SC, Austin DF, Sheppard BC, et al. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg 2009; 208:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/129\">",
"      Zamboni GA, Kruskal JB, Vollmer CM, et al. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology 2007; 245:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/130\">",
"      Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001; 88:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/131\">",
"      Fern&aacute;ndez-del Castillo C, Warshaw AL. Laparoscopy for staging in pancreatic carcinoma. Surg Oncol 1993; 2 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/132\">",
"      del Castillo CF, Warshaw L. Peritoneal metastases in pancreatic carcinoma. Hepatogastroenterology 1993; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/133\">",
"      Yamada S, Takeda S, Fujii T, et al. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg 2007; 246:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/134\">",
"      Meszoely IM, Lee JS, Watson JC, et al. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg 2004; 70:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/135\">",
"      Yachida S, Fukushima N, Sakamoto M, et al. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 2002; 89:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/136\">",
"      Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/137\">",
"      Merchant NB, Conlon KC, Saigo P, et al. Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 1999; 188:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/138\">",
"      Hartwig W, Schneider L, Diener MK, et al. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 2009; 96:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/139\">",
"      van Heerde MJ, Biermann K, Zondervan PE, et al. Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig Dis Sci 2012; 57:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/140\">",
"      Abraham SC, Wilentz RE, Yeo CJ, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol 2003; 27:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/141\">",
"      Smith CD, Behrns KE, van Heerden JA, Sarr MG. Radical pancreatoduodenectomy for misdiagnosed pancreatic mass. Br J Surg 1994; 81:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/40/41610/abstract/142\">",
"      de la Fuente SG, Ceppa EP, Reddy SK, et al. Incidence of benign disease in patients that underwent resection for presumed pancreatic cancer diagnosed by endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). J Gastrointest Surg 2010; 14:1139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2501 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41610=[""].join("\n");
var outline_f40_40_41610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158746930\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18017807\">",
"      Incidental finding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158746981\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158747091\">",
"      Jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158747200\">",
"      Epigastric pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163256719\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158747219\">",
"      Pancreatic mass seen on an imaging study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158747298\">",
"      Initial testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163255339\">",
"      - Jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163255347\">",
"      - Epigastric pain and weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163255239\">",
"      - Subsequent testing if initial imaging is positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H158747860\">",
"      - Subsequent testing if initial imaging is negative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158747285\">",
"      Specific tests used in the initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163254646\">",
"      - Transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163255596\">",
"      - Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21056075\">",
"      - ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1617931\">",
"      - MRCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1620032\">",
"      - Role of tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1620046\">",
"      CA 19-9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1620094\">",
"      Other markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2362725\">",
"      Biopsy and establishing the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2362986\">",
"      - Percutaneous biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2363690\">",
"      - EUS-guided biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18017084\">",
"      STAGING SYSTEM AND THE STAGING WORKUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18176032\">",
"      - Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11417555\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Assessing resectability",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1472388\">",
"      - Definitions of unresectable and borderline resectable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1472545\">",
"      - Accuracy of CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1472183\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H937783\">",
"      Chest CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PET scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1618421\">",
"      Staging laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1618501\">",
"      - Importance of peritoneal cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363341\">",
"      DIAGNOSTIC ALGORITHM AND NEED FOR PREOPERATIVE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2501|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/37/19038\" title=\"algorithm 1\">",
"      Classification jaundice II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/37/36432\" title=\"algorithm 2\">",
"      Dx pancreatic cancer algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2501|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/59/33718\" title=\"diagnostic image 1\">",
"      CT panc adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/9/27794\" title=\"diagnostic image 2\">",
"      Contrast MDCT panc mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/60/965\" title=\"diagnostic image 3\">",
"      Pancreatoscope on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/47/22263\" title=\"diagnostic image 4\">",
"      CT vascular encasement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/58/12198\" title=\"diagnostic image 5\">",
"      Contrast CT panc neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/15/38133\" title=\"diagnostic image 6\">",
"      T2 T1 MRI panc adeno",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/9/31893\" title=\"diagnostic image 7\">",
"      PET CT panc head mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2501|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/32/38407\" title=\"figure 1\">",
"      Pancreatic panniculitis in patient w acinar cell panc cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/49/5908\" title=\"figure 2\">",
"      Locations ampullary tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2501|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/28/33220\" title=\"picture 1\">",
"      Double duct sign in pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/18/3375\" title=\"picture 2\">",
"      Cytology pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/55/28541\" title=\"table 1\">",
"      Classification of jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/11/3259\" title=\"table 2\">",
"      Cond assoc increased CA 19-9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/32/43532\" title=\"table 3\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/60/34763\" title=\"table 4\">",
"      Grading system predicting vascular invasion by pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=related_link\">",
"      Approach to the patient with weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19816?source=related_link\">",
"      Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14471?source=related_link\">",
"      Endoscopic ultrasound guided trucut biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=related_link\">",
"      Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8884?source=related_link\">",
"      Endoscopic ultrasound: Normal pancreaticobiliary anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=related_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_40_41611="Miscarriage rate after amnio";
var content_f40_40_41611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Miscarriage rate after amniocentesis in series utilizing ultrasound guidance during the procedure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Author",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Spontaneous abortions",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Difference in rates (95% confidence interval)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Cases (numbers)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Controls (number)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tabor (1986)",
"      </td>",
"      <td>",
"       1.7% (38/2242)",
"      </td>",
"      <td>",
"       0.7% (17/2270)",
"      </td>",
"      <td>",
"       0.9% (0.3%; 1.5%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Andreasen (1989)",
"      </td>",
"      <td>",
"       2.3% (30/1318)",
"      </td>",
"      <td>",
"       1.4% (4/276)",
"      </td>",
"      <td>",
"       0.8% (-1.3%; 1.9%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tongsong (1998)",
"      </td>",
"      <td>",
"       1.8% (36/2045)",
"      </td>",
"      <td>",
"       1.4% (29/2045)",
"      </td>",
"      <td>",
"       0.3% (-0.4%; 1.1%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antsaklis (2000)",
"      </td>",
"      <td>",
"       2.1% (79/3696)",
"      </td>",
"      <td>",
"       1.5% (80/5324)",
"      </td>",
"      <td>",
"       0.6% (0.1%; 1.2%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eddleman (2006)",
"      </td>",
"      <td>",
"       1.0% (31/3096)",
"      </td>",
"      <td>",
"       0.9% (300/31,907)",
"      </td>",
"      <td>",
"       0.1% (-0.3%; 0.5%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kong (2006)",
"      </td>",
"      <td>",
"       1.7% (58/3465)",
"      </td>",
"      <td>",
"       0.8% (9/1125)",
"      </td>",
"      <td>",
"       0.9% (0.1%; 1.4%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Odibo (2008)",
"      </td>",
"      <td>",
"       0.97% (113/11,695)",
"      </td>",
"      <td>",
"       0.84% (335/39,594)",
"      </td>",
"      <td>",
"       0.13% (-0.07%; 0.20%)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    An increase in rate of spontaneous abortion compared with controls was seen in all study groups following amniocentesis, although the difference did not reach significance in four series.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41611=[""].join("\n");
var outline_f40_40_41611=null;
var title_f40_40_41612="Hand examination";
var content_f40_40_41612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examination of the hand",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination",
"signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bony enlargement of the distal",
"interphalangeal (DIP) or proximal interphalangeal (PIP) joints**",
"        <br/>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        #1 - Osteoarthritis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Hand x-rays (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness",
"and decreased flexion or extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal",
"signs of inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of",
"smooth motion of the PIP joint - \"triggering\"**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        #2 - Trigger finger",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Local anesthetic block at the",
"flexor tenosynovium (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness",
"of the flexor tendons over the metacarpophalangeal (MCP) joint in the",
"palm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain reproduced by",
"passive extension of the finger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        <p>",
"         Synovial thickening, swelling",
"of the DIP, PIP, and MCP joints**",
"        </p>",
"        <p>",
"         Stiffness and decreased",
"flexion or extension",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Inflammatory arthritis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Clinical diagosis, ESR, hand",
"x-rays, serologies (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psoriatic",
"arthritis (DIP joints)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatoid",
"arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thickening of the",
"flexor tendons of the palm**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Dupuytren's contracture",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss",
"of full extension of the fingers due to contracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic",
"swelling of the flexor tendons near the MCP joint**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Tenosynovial cyst",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cyst aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"finger range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness",
"of the MCP joint to palpation**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Monoarticular posttraumatic arthritis of the MCP",
"joint",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Lidocaine",
"injection of joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MCP joint",
"squeeze sign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to",
"fully extend the DIP joint and characteristic flexion deformity**",
"       </td>",
"       <td>",
"        Mallet",
"finger",
"       </td>",
"       <td>",
"        Clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pale",
"grey colored 3 to 5 mm cyst overlying the DIP or PIP joint**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Mucinoid cyst",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated",
"osteoarthritic signs of the adjacent joint",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ** is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"     <br>",
"      #1 and #2 refer to the most common conditions affecting the hand.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41612=[""].join("\n");
var outline_f40_40_41612=null;
var title_f40_40_41613="Contents: Selected end stage conditions";
var content_f40_40_41613=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?34/55/35709\">",
"       Palliative Care",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Selected end stage conditions",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Selected end stage conditions",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/53/36694\">",
"           Palliative care: End-stage renal disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/56/19337\">",
"           Hypoxic-ischemic brain injury: Evaluation and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/12/17610\">",
"           Medical complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/26/33193\">",
"           Symptom-based management of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/6/33896\">",
"           Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/50/37673\">",
"           Management and prognosis of patients requiring prolonged mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/28/3528\">",
"           Respiratory muscle weakness due to neuromuscular disease: Management",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8782691295-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_40_41613=[""].join("\n");
var outline_f40_40_41613=null;
var title_f40_40_41614="Lateral foot x-ray with metatarsal shaft fracture";
var content_f40_40_41614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral foot x-ray with metatarsal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow indicates a fracture of the third metatarsal. However, the lateral view is less useful than the oblique and AP views because of overlapping of the metatarsals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41614=[""].join("\n");
var outline_f40_40_41614=null;
var title_f40_40_41615="Chagas heart radionuclide angio";
var content_f40_40_41615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Radionuclide angiogram in chronic Chagas disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient has chronic Chagas disease and megesophagus but no clinical signs of cardiac invovlvement. The radionuclide angiogram shows preservation of left ventricular function but moderate right ventricular dysfunction with an ejection fraction (EF) of 37 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_40_41615=[""].join("\n");
var outline_f40_40_41615=null;
